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Tight regulation of the Wnt/β-catenin pathway is crucial not only at all stages of 
embryonic cardiac development but also for maintaining normal adult heart 
homeostasis. Indeed, activation of the Wnt/β-catenin signaling is associated with 
pathological heart remodeling. A better understanding of the fine tuning of the Wnt-off 
and -on -states in the progression of cardiac failure is attractive to identify potential 
targets for blocking pathological remodeling and/or activating endogenous tissue 
regeneration. This work focused on the identification of a tissue specific regulator of 
this cascade in the heart, which remains elusive. 
 
Previous data in the group identified the basic leucine zipper and W2 domains 
containing protein (BZW) 2 as a β-catenin and KLF15 cardiac interaction partner. The 
role of BZW2 in Wnt signaling in cardiogenesis and adult cardiac homeostasis was 
specifically addressed in this study. Analysis of the BZW2 protein showed that the 
putative ZIP and bZIP containing domain is important for nuclear localization, 
suggesting its role in the nucleus. BZW2 expression was found prominent in the adult 
heart but also during cardiac embryogenesis. Low BZW2 expression was required for 
effective cardiac mesoderm formation as found by abrogation of cardiomyocytes 
formation upon BZW2 overexpression in an in vitro cardiogenesis model. However, 
BZW2 expression was not crucial for embryogenesis, which could be based on 
compensatory function of related proteins. Interestingly, BZW2 was necessary to 
maintain normal cardiac function and during stress induced response. Regarding the 
Wnt/β-catenin signaling, although BZW2 did not significantly induce inhibition of the 
Wnt transcriptional activity in vitro, the lack of BZW2 resulted in de novo synthesis of 
β-catenin specifically in the adult heart tissue in vivo. Moreover, BZW2 was found to 
be regulated downstream of the Wnt/β-catenin signaling suggesting its role as a 
regulatory feedback factor in vivo. 
 
In summary, this study identified a novel heart tissue component of the Wnt/β-catenin 
pathway with a new level of regulation and demonstrated its relevance to maintain 
normal heart homeostasis. Given the ubiquitous expression and multiple functions of 




Die Regulation des Wnt/β-catenin Signalwegs ist nicht nur entscheidend für alle 
Stadien der kardialen Entwicklung, sondern auch für die Homöostase im adulten 
Herzen. Tatsächlich ist die Aktivierung des Wnt/β-catenin Signalwegs mit dem 
pathologischen Herz-Remodeling assoziiert. Ein besseres Verständnis der 
Regulation des Wnt/β-catenin Signalwegs bei Herzinsuffizienz könnte die 
Identifikation potentieller Faktoren zum Blockieren des pathologischen Herz-
Remodelings und/oder das Aktivieren der endogenen Regeneration ermöglichen. 
Diese Arbeit konzentriert sich auf die Identifikation von gewebespezifischen 
Regulatoren des Wnt/β-catenin Signalwegs im Herzen. 
Frühere Arbeiten unserer Gruppe identifizierten basic leucine zipper and W2 domains 
containing protein (BZW) 2 als einen kardialen Interaktionspartner von β-catenin und 
KLF15. Die Rolle von BZW2 im Wnt/β-catenin Signalweg bei der Kardiogenese und 
der Homöostase des adulten Herzens war das Thema dieser Studie. Eine Analyse 
des BZW2-Proteins zeigte, dass die mutmaßliche ZIP und bZIP umfassende 
Domäne wichtig für die nukleare Lokalisation ist. Die Expression von BZW2 hat sich 
als bedeutsam im adulten Herzen, aber auch während der embryonalen  
Kardiogenese erwiesen. Eine niedrige BZW2-Expression ist für die effektive Bildung 
des kardialen Mesoderms notwendig, denn es kam unter BZW2-Überexpression zu 
einem Abbruch der Kardiomyozytenbildung in einem Modell der in vitro 
Kardiogenese. Dennoch war die BZW2-Expression nicht entscheidend für die 
Embryogenese, was auf eine kompensatorische Funktion verwandter Proteine 
hindeuten könnte. Interessanterweise war BZW2 für den Erhalt der normalen 
Herzfunktion und während der Reaktion auf Stress notwendig. Obwohl BZW2 die 
Wnt-Transkriptionsaktivität in vitro nicht signifikant inhibiert hat, resultierte das Fehlen 
von BZW2 in de novo Synthese von β-catenin spezifisch im adulten Herzgewebe in 
vivo. Außerdem wurde BZW2 selbst durch den Wnt/β-catenin Signalweg reguliert, 
was auf seine Rolle als regulatorischer Rückkopplungsfaktor in vivo hindeutet. 
Zusammenfassend identifizierte diese Arbeit einen neuen herzgewebespezifischen 
Faktor des Wnt/β-catenin Signalwegs auf einer neuen Regulationsebene und 
demonstrierte seine Relevanz für die normale Herzhomöostase. Angesichts der 
ubiquitären Expression und der vielfältigen Funktionen von β-catenin könnte die 




1.1. Heart failure 
Insufficient pump function of the heart as found in heart failure condition is one of the 
most common causes of death affecting over 23 million people worldwide.1 In 
Germany heart failure is on the 3rd place of death causes.2 Beside congenital 
cardiomyopathies, the main risk factors for heart failure are obesity, diabetes, 
dyslipidemia, hypertension, infections, alcoholism and tobacco among others.3 
The main problem is that upon injury the absence of a robust regenerative response 
results in muscle loss and contractile decay, which ultimately leads to a failing heart.4 
Currently, available pharmacological treatments are delaying but not preventing the 
onset of heart failure. Upon stress the heart undergoes tissue remodeling, which is a 
biological adaptation process of the failing heart. A common feature of the 
hemodynamically or metabolically stressed heart is a switch towards “fetal” 
metabolism and re-expression/elevation of fetal genes. They include genes encoding 
proteins involved in signaling pathways (NF-κB, SRF, SMADs, EGR1 or CREB, FZ, 
Axin, WNT) and cardiac transcription factors (MEF2, GATA4, NKX2.5, HAND, TBX5), 
some of them (SMADs, CREB, FZ, WNT, MEF2, GATA4, NKX2.5, HAND, TBX5) are 
involved in embryonic heart development.5-9 However, the pathophysiological 
relevance of this re-expression in diseases progression remains still unclear. 
1.1.1. Pathological cardiac remodelling and current therapies 
Before reaching the heart failure stage, the heart undergoes a process of remodeling, 
a compensatory response, which initially intends to maintain the pump function. 
However, long-term activation of this remodeling upon sustained stimulus contributes 
to progressive deterioration and culminates in heart failure. Morphologically, 
pathological cardiac remodeling involves cardiac myocytes growth and death, 
vascular remodeling, fibrosis and inflammation, which lead to change in the heart 
geometry namely less elliptical and more spherical.10 
The stress-induced compensatory response involves mechanical changes leading to 
increase in myocardial fiber length and an increase in the force of contraction, up to a 
certain point. This is accompanied by a series of neuroendocrine regulation in 
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response to the damaged muscle and impaired function due to the tendency of the 
cardiac output to decrease. Neuroendocrine adaptation includes activation of 
sympathetic nervous system and renin-angiotensin-aldosterone-system (RAAS, a 
hormonal system regulating blood pressure and fluid balance), both of them trying to 
restore and maintain cardiac output and blood pressure. These long-term 
compensation mechanisms become counterproductive, the heart dilates, wall stress 
increases and the heart muscle becomes weak. This is vicious cycle, which 
progresses to heart failure. 
As mentioned above activation of embryonic pathways are suggested to play an 
important early role in the process of heart remodelling. Because the elucidation of 
these pathways may help to develop novel pharmacological strategies to support 
myocardial regeneration, many of the cardiac-restricted factors originally 
characterized within a purely developmental context are now becoming significant in 
translational cardiac research.6, 11 
 
Currently established therapies delay the progression of heart failure symptoms but 
do not prevent the development of end stage heart failure. They are mainly aiming to 
stop the vicious cycle at different point such as targeting the RAAS system with ACE-
inhibitors; ameliorating the sympathetic nervous system response by β-adrenergic 
receptor blockers; or decreasing volume by reduction of preload and afterload with 
Diuretics. Cardiac glycosides (digitalis) are used in acute heart failure to increase 
contractility and decrease heart rate by increasing intracellular calcium. Ultimately, in 
heart failure progression surgical and technical therapies are used, up to heart 
transplantation when pharmacological treatments failed.12 It is evident, that all these 
therapies cannot prevent the progression of heart muscle decay and/or reverse 
damage. Therefore, new therapeutic approaches under investigation try to focus on 
prevention of heart failure progression by either blocking cellular deterioration or 
enhancing the hearts own regeneration. The latter can be achieved by stimulation of 
resident cell sources (cardiac progenitor differentiation and cardiomyocytes 
proliferation) or direct cellular reprogramming of cardiac fibroblasts.13-15 Other 
promising approaches under investigation are cell transplantation (ESCs/iPSCs, 
cardiac progenitors and cardiomyocytes) and tissue engineering.16, 17 For blocking 
cellular deterioration, it is imperative to get insight into the molecular mechanisms 
responsible for maintaining normal cardiac homeostasis. This study focused on such 
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a signaling, namely the Wnt pathway, whose tight regulation is essential for 
maintaining normal heart function.  
1.2. Heart regeneration 
The traditional view of the heart as a terminally differentiated organ without any 
capacity for cardiomyocyte renewal has been challenged in the last years in several 
studies.18-21 Current evidences suggest that the mammalian heart possesses a 
capacity for repair through cardiomyocyte de-differentiation followed by proliferation 
and re-differentiation or endogenous cardiac progenitor cells (CPCs) activation or 
maybe a combination of both 13, 19-22. However, these mechanisms are insufficient to 
replace severely damaged myocardium under regular pathological circumstances. 
Taking advantage of the integration of 14C (generated by nuclear bomb tests during 
the Cold War) into DNA it was shown that adult human heart possess a 
cardiomyocytes renewal rate of 1% per year at the age of 20 and 0.3% at the age of 
75 in the normal heart homeostasis.20, 23 Moreover, by combining two different pulse-
chase approaches in mice it has been demonstrated that cardiomyocytes genesis is 
dominantly by division of pre-existing cardiomyocytes during normal aging, a process 
that increases by four-fold adjacent to areas of myocardial injury21 although 
cardiomyocytes derived from CPCs accounted for a 20% of the new formed 
cardiomyocytes. Another study demonstrated full regeneration of injured hearts in 1-
day old mice characterized by cardiomyocytes proliferation with minimal hypertrophy 
or fibrosis. This regenerative capacity was lost in murine heart by 7 days of age.24 
Further approaches using embryonic stem cells (ESCs) for transplantation of 
functional cardiomyocytes in animal models have begun to show promising results.17 
Multiple studies have demonstrated engraftment of mouse ESC-derived 
cardiomyocytes to improve contractile function when transplanted to rodent.25 
Understanding the mechanisms regulating cardiomyocyte generation and 
participating in the process of heart remodelling will be the basis not only for 
designing new therapeutic targets enhancing/blocking the heart’s own mechanisms 
but also for optimization of cardiomyocyte derivation from stem cells for applications 
in studies of fundamental heart muscle biology, drug discovery, and potentially also 




1.3.1. Morphologic view 
The vertebrate heart is the first organ that becomes functional during embryogenesis. 
Cardiac precursor cells are found before gastrulation bilaterally distributed in the 
posterior epiblast directly adjacent to the primitive streak. Additionally, cardiac 
precursors are found in the upper third of the primitive streak under Hensen’s node 
(in mouse embryonic post coitum day E4.5). The mesoderm is built during 
gastrulation by cell migration from primitive streak between ectoderm and endoderm. 
After specification the pre-cardiac mesoderm migrates from the primitive streak in an 
anterolateral direction. These cells will form the heart-forming fields on either side of 
the primitive streak in endocardial tubes (E5.5-6.0). Cell specification may occur 
when the cells are organized in the heart fields. Prospective heart cells with a cranial 
position will form anterior structures of the tubular heart, while more caudally 
localized cells will form posterior structures. Then, two endocardial tubes migrate 
anterior-medial and subsequently fuse at the anterior ends to the first distinct cardiac 
structure, the cardiac crescent (E6.5-7.5) (Figure 1A). First heart field (FHF) 
progenitor cells (caudal crescent) start to differentiate. The cardiac crescent forms 
the beating, linear heart tube (Figure 1B). Second heart field (SHF) progenitors 
gradually migrate into the linear heart tube and differentiate (E8.0). After rightward 
looping of the linear heart tube (E8.5) cardiac neural crest cells contribute to the 
heart, which already shows defined four-chamber morphology (E10.5) (Figure 1C). At 
E14.5, the heart shows four fully separated chambers (FHF differentiates to the left 
ventricle and SHF to the right ventricle and a large portion of the atria) and the 
outflow tract (differentiated from SHF) connected to the pulmonary trunk and the 





Figure 1: Four morphological stages of the cardiogenesis in mouse. 
Cr = cranial; Ca = caudal; R = right; L = left. A The cardiac crescent (here shown at E7.75) is the first 
distinct cardiac structure and is built at E6.5-7.5 by anterior-medial migration of two endocardial tubes 
and theirs subsequently fusion at the anterior ends. FHF cells start to differentiate. B At E8.0 the 
cardiac crescent forms the beating, linear heart tube (here shown at E8.25) by FHF cells differentiation 
and SHF cells migration and differentiation. C After rightward looping, cardiac neural crest and pro-
epicardial cells contribute to the heart, which already shows defined four-chamber morphology 
(E10.5). FHF cells differentiate mainly to the left and right ventricles. SHF cells differentiate into 
outflow tract, the right ventricle and a large portion of the atria. D At E14.5 (here shown at E12.5) the 
heart shows four nearly fully separated chambers and the outflow tract connected to the pulmonary 
trunk and the dorsal aorta. 
(Adapted from Harvey RP, review, 2010)
32
 
1.3.2. Molecular aspects of cardiogenesis 
Mesoderm induction, an evolutionary conserved process, is the first step before 
cardiogenesis and is regulated by numerous conserved signaling pathways (Nodal, 
BMP, Wnt, FGF).31, 33, 34 During ingression of mesoderm cells through the primitive 
streak Wnt/β-catenin signaling activation induces Brachyury (Bry) expression and 
leads to mesoderm progenitors (BRY+) formation.31, 35 Inactivation of Wnt/β-catenin 
signaling and activation of non-canonical Wnt signaling lead to induction of primordial 
cardiovascular progenitors (BRY+/FLK1+).36-38 At this step, endoderm provides 
mesoderm with inductive signals, the growth factors including BMPs, FGFs, and Wnt 
proteins.39, 40 The following cardiogenic mesoderm specification occurs upon 
downregulation of Bry and activation of mesoderm posterior (MESP) 1 expression by 
eomesodermin.37, 38 Because of their cranial position in the cardiac crescent, FHF 
progenitors are exposed to cytokines of the BMP41 and FGF42 families as well as to 
inhibitors of the Wnt/β-catenin pathway43-45, resulting in cardiac differentiation marked 
by expression of key regulators NKX2.5, GATA-4 and TBX5.31, 46 Cardiomyocytes 
commitment is evident by expression of myosin light chain (MLC) 2a and sarcomeric 
myosin heavy chain (MHC) expression.47 SHF cells remain in a proliferative, 
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undifferentiated progenitor state in the cardiac crescent and are marked by LIM-
homeo-domain transcription factor 1 (ISL-1).48, 49 ISL-1 expression is dependent on 
Wnt/β-catenin signaling50, 51 and is required for SHF cells survival, proliferation and 
migration into the heart tube.31 When SHF cells reach the heart tube, ISL-1 
expression decreases and differentiation takes place.52 
1.3.3. Wnt/β-catenin signalling in cardiogenesis 
Wnt/β-catenin signaling pathway is essential for cardiogenesis. It regulates heart 
development in a multiphasic manner beginning with mesoderm formation through all 
developmental steps up to the formed heart.31, 36 
It was shown that β-catenin knock-out mice fail to generate mesoderm.53 Moreover, 
early inhibition of the Wnt/β-catenin signaling blocks expression of mesoderm-
specific marker genes in murine ESCs. It results in a loss of MESP1 and 
downregulation of FLK1 expression.54 It was shown that the Bry promotor includes 
TCF binding site, suggesting that mesoderm formation depends on Wnt/β-catenin 
signaling using Bry expression.55, 56 These data together indicate that Wnt/β-catenin 
activation is essential for mesoderm formation36 (Figure 2). Furthermore, cardiogenic 
mesoderm formation from mesodermal precursors (process of the cardiac 
specification) depends on the Wnt/β-catenin inactivation36 (Figure 2). It was shown 
that Wnt/β-catenin signaling supports the expansion of committed cardiac progenitor 
cells.36, 57 Mice expressing stabilized β-catenin display enlarged ventricles, more cells 
and upregulated Cyclin D2. Mice with a depleting β-catenin function display smaller 
ventricles and reduced proliferation.57 All these data together indicate that Wnt/β-
catenin signaling promotes cell proliferation in cardiogenesis36 (Figure 2). 
Addition of Wnt3a decreased differentiation of ESC-derived cardiomyocyte during 
embryo body (EB) differentiation58, 59 as well as ISL-1+ CPCs differentiation60. 
Overexpression of stabilized β-catenin in ISL-1+ CPCs results in a downregulation of 
several important cardiac genes at E9.0 in mouse.61 These data together indicate 






Figure 2: Schematic representation of time specific regulatory role of the Wnt/β-catenin 
signaling pathway during cardiogenesis. 
Wnt/β-catenin signaling needs to be active during mesoderm formation and proliferation but inactive 
during cardiac specification. Inactive Wnt/β-catenin signaling leads to terminal cardiomyocytes 
differentiation. Information collected from Ueno S et al., 2007
58
; Naito AT et al., 2006
59
; Qyang Y et al., 
2007
60
; Gessert S & Kühl M, 2010
36
. 
1.4. Wnt/β-catenin signaling pathway 
Transduction of the Wnt signal involves complex protein-protein interactions with 
regulatory inputs at many distinct levels including membrane receptors, cytoplasmic 
and nuclear protein complexes. In absence of Wnt, β-catenin, the key transduction 
protein of the Wnt/β-catenin signaling, is sequestered in a destruction protein 
complex and the pathway is inactive (Figure 3A). The complex includes Axin2, 
adenomatosis polyposis coli (APC), protein phosphatase (PP) 2a, glycogen synthase 
kinase (GSK) 3β and casein kinase (CK) 1α. CK1α phosphorylates β-catenin at 
Ser45, which is followed by phosphorylation at Ser33, Ser37 and Thr41 by GSK3β. 
The phosphorylation sites are recognized by the beta-transducin repeat containing 
E3 ubiquitin protein ligase (βTrCP) and β-catenin is ubiquitinated and targeted to 
proteasome for degradation. In the presence of Wnt, it binds to the Frizzled (FZ) 
receptor and the co-receptor lipoprotein receptor-related protein (LRP) 5/6, which 
becomes phosphorylated and activated (Figure 3B). The destruction complex and 
phosphoprotein Dishevelled (DVL) are sequestered to the plasma membrane 
becoming inactive. Axin2 binds to the cytoplasmatic tail of LRP-5/6 and becomes 
dephosphorylated. DVL binds to FZ, becomes activated by phosphorylation and 
inhibits GSK3β activity. Thus β-catenin cannot be phosphorylated and degraded, 
accumulates in cytosol and becomes translocated into the nucleus. In nucleus, after 
a certain level of β-catenin is reached, it binds to T-cell factor / lymphoid enhancing 
factor (TCF/LEF) transcription factors, displacing the bound repressors and activating 
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the cascade. Interaction of further specific co-factors activates the Wnt/β-catenin 
signaling target gene transcription. The Wnt/β-catenin signaling is inhibited 
extracellularly by binding of Dickkopf-related protein (DKK) 1 to LRP-5/6 or by binding 
of secreted frizzled-related protein (sFRP) to Wnt or to FZ. Intracellular inhibition 
occurs by a negative feedback loop mechanism, when target genes are a part of the 
destruction complex, like Axin2, or when they block gene transcription in nucleus by 
binding to TCF/LEF.62-67 
 
 
Figure 3: Schematic view of Wnt/β-catenin signaling. 
A When Wnt/β-catenin signaling is inactive the key protein β-catenin is bound by destruction protein 
complex, including APC, PP2A, GSK3 and CK1α. β-catenin becomes phosphorylated by GSK3 and 
CK1α and targeted to the proteasome for degradation. B In the presence of Wnt the signaling 
becomes activated. The destruction complex and DVL are sequestered to the plasma membrane. DVL 
inhibits GSK3 and β-catenin accumulates in cytosol and subsequently in the nucleus where it binds to 
TCF/LEF and activates gene transcription. 
(MacDonald BT et al., 2009)
62
 
1.4.1. Wnt/β-catenin signaling in the adult heart 
The role of Wnt in cardiogenesis is very well described; however its role in adult heart 
homeostasis is not completely understood. In normal adult cardiomyocytes the 
activity of the Wnt/β-catenin signaling is low.68 However, Wnt/β-catenin signaling is 
activated in the whole heart in response to cardiac injury in adult mammals and 
several evidences showed important roles in hypertrophy and cardiac remodeling.69 
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Although the current studies are controversial regarding the role of Wnt/β-catenin 
signaling in heart failure, there are consistent evidences showing upregulation of 
components of the Wnt/β-catenin signaling in different cardiac injury models. In 
hypertrophic hearts FZ as well as β-catenin were found to be upregulated.70, 71 DVL-1 
was found to be upregulated in TAC operated rat hearts as wells as in post-ischemic 
hearts.72, 73 Moreover, Axin2 and Dapper1 (DPR1, Wnt signaling antagonist via DVL 
degradation) were found upregulated in post-ischemic hearts.74-76 Regulatory 
response seems to depend on injury model and the level at which the signaling 
cascade is modified. To investigate the role of β-catenin in adult heart under 
diseased conditions, several studies used transgenic mouse lines with cardiac 
specific inducible deletion as well as stabilization of β-catenin. Depletion of β-catenin 
depending on α-Mhc promoter in the adult heart leads to a significant preserved left 
ventricle function and survival four week after infarction.77 In unstressed heart 
prolonged β-catenin stabilization led to impaired cardiac function.78 Moreover, β-
catenin stabilization led to an abrogated compensatory hypertrophic response to Ang 
II treatment79 and after TAC80. In contrast, in other studies β-catenin stabilization was 
described to be required for cardiac hypertrophy.71, 80, 81 Mice expressing a non-
degradable form of β-catenin in Mlc2v expressing cells developed cardiac 
hypertrophy followed by dilated cardiomyopathy with increased mortality.81 Altogether 
these studies reflect the importance of a tight Wnt/β-catenin signaling regulation in 
the adult heart. However, the molecular mechanisms determining context-specific 
regulation and responses of the ubiquitous Wnt/β-catenin pathway in adult heart cells 
remain largely unknown. Understanding of the fine tuning of the Wnt-off/-on state is 
essential to prevent heart progression and to maintain/preserve normal cardiac 
function. 
1.4.2. Cardiac specific regulation of the Wnt/β-catenin signalling 
Based on the conservation of the pathway and its relevance in the process of 
cardiogenesis, the Wnt/β-catenin signaling offers a suitable target for tissue 
regeneration. Thus, understanding the mechanisms of Wnt/β-catenin regulation in 
heart failure offers the potential to develop new therapeutic approaches. However, 
the knowledge of a tissue specific regulation of this ubiquitously expressed pathway 
is currently missing. Previous work in our group reported a novel level of regulation in 
the Wnt/β-catenin signaling namely the Krueppel-like factor (KLF) 15, which inhibits 
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Wnt/β-catenin transcriptional activity and controls CPC fate in the postnatal heart.78 
In line with its inhibitory role, a global Klf15 functional knock-out mouse showed 
upregulation of Wnt/β-catenin transcriptional activity as demonstrated by Tcf7l2 and 
c-Myc upregulation specifically in heart tissue (Figure 4A; Noack C et al., 
unpublished), although Klf15 is highly expressed in other organs beside the heart 
(Figure 4B; Noack C et al., unpublished). This indicates the requirement of additional 
tissue specific co-factors for this regulation. 
 
 
Figure 4: Klf15 KO mice and Klf15 expression in different organs. 
A Tcf7l2 mRNA expression normalized to β-actin in different organs of Klf15 knock-out (KO) mice 
(heart, lung, liver and kidney; n=5/group, Student’s t-test, **p<0.001) analyzed by qPCR showing 
cardiac specific Wnt/β-catenin signaling upregulation in Klf15 KO mice. B Klf15 mRNA expression 
normalized to β-actin in different murine organs (heart, skeletal muscle, brain, liver, kidney, spleen and 
lung; n=5) analyzed by qPCR showing that Klf15 is not predominantly expressed in the heart (Noack C 
et al., unpublished). 
 
In order to identify such factors, a yeast-2-hybrid screen was performed using a 
human cardiac library (kindly provided by Norbert Frey, University Kiel) and β-catenin 
as well as KLF15 as prey proteins. Only six proteins were found to bind both β-
catenin and KLF15, among which basic leucine zipper and W2 domains containing 
protein (BZW) 2 was found (Renger A et al., unpublished). The putative nuclear 
localization of BZW2 and data showing high expression in the adult rat heart82-85 
prompted us to select this candidate for further investigation among the others.  
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1.5. BZW2 protein 
BZW2 is an evolutionary highly conserved protein as appreciated in Figure 5, which 
shows the comparison of its peptidic sequence among Homo sapiens, Mus 
musculus, Gallus gallus, Xenopus tropicanis, Danio rerio and Drosophila 
melanogaster, however nothing is known about its function in the heart. BZW2 
belongs to the BZW protein family consists of BZW2 and homologue BZW1. Via 
Northern blot analysis it was shown that Bzw2 mRNA is predominantly expressed in 
the adult rat heart in comparison to brain, spleen, lung, liver, skeletal muscle, kidney 
and testis. Bzw2 RNA is highly expressed during rat brain development (E12.0-20.0) 
and rapidly decreases after birth (postnatal day P2), which allows concluding that 
BZW2 should have a role in neurogenesis. The local specific RNA expression in the 
adult rat brain (especially in cerebellum) was demonstrated via in situ hybridization.82 
In another study BZW2 was shown to bind to eukaryotic initiation factors (eIF) 2 and 
3 in HeLa cells in vitro. Furthermore BZW2 inhibits protein synthesis in rabbit 
reticulocyte lysate (RRL) system, an in vitro system testing expression activity. 
Interestingly BZW2 seems to increase translation of activating transcription factor 
(ATF) 486, which is crucial for osteoblast differentiation87. Overexpression of a Bzw2-
transcript in HeLa cells showed cytosolic localization.86 Furthermore, upregulation of 
Bzw2 was detected in different human lymphomas via microarray.88 To best of my 





Figure 5: Alignment of the BZW2 protein in different organisms. 
BZW2 protein in Homo sapiens (NP_001153239.1), Mus musculus (NP_080116.2), Gallus gallus 
(NP_001006358.2), Xenopus tropicanis (XP_002933339.1), Danio rerio (NP_957212.1) and 
Drosophila melanogaster (NP_730958.1). Color code for amino acids: non-polar/hydrophobic (light 
blue), polar/hydrophilic (green), basic (red), acidic (magenta) and others (yellow, orange, blue). 
Introduction 
13 
Structurally Bzw2 transcript includes 12 exons (Figure 6). The transcription starts in 
exon 2 and ends in exon 12. BZW2 protein is 48 kDa in size and includes an N-
terminal basic leucine zipper domain (bZIP) and a C-terminal W2 domain. 
 
 
Figure 6: Schematic view of human / murine Bzw2 transcript. 
The transcript includes 12 exons. The coding sequence (CDS) starts in exon 2 and ends in exon 12. 
The putative ZIP domain is coded by exon 3. The following putative bZIP domain is coded by exons 4-
6 and includes an N6-acetyllysine. The W2 domain is coded by exons 8-11 and is following by two 
phosphoserines. 
 
C-terminal W2 domain is typical for translation initiation factors. It contains two 
aromatic/acidic residue-rich regions, which are important for mediating protein-protein 
interactions.89, 90 In BZW2 protein the W2 domain is coded by exons 8-11 (NCBI, 
NP_001153239.1, NM_001159767.1). The bZIP domain is typical for transcription 
factors. It consists of a basic region mediating sequence specific DNA binding 
properties and the leucine zipper requiring holding of two DNA binding regions 
together.84 The basic region of the bZIP domain is described to include the 
conserved sequence “asparagine (N) – x7 – arginine (R) / lysine (K)”84 or “N – x9 – 
R/K”83 and to consist of approximately 16 amino residues. Exactly 9 amino acids in 
C-terminal direction starts the leucine zipper region of the bZIP domain. It consists of 
a repetition of leucine (L) or other hydrophobic amino acids (isoleucine (I), valine (V), 
phenylalanine (F) or methionine (M)) at every seventh position and forms α-helices.84 
Human and murine BZW2 proteins include a nearly identical 74 amino acids long 
construct in the N-terminus coding by exons 4-6: “histidine (H) 105 – N110 – x9 – 
R120” (as basic region) – x8 – “F129 – x6 – L136 – x6 – F143 – x7 – L151 – x6 – 
L158 – x5 – L164 – x7 – L172 – x5 – V178” as ZIP region (Figure 6 and Figure 7). 
Here is important to mention that not all hydrophobic amino acids, in the leucine 
zipper region of the putative bZIP domain, are found on the exactly seventh position 
in BZW2. Furthermore analysis of the human and murine BZW2 protein sequences 
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revealed an N-terminal region suitable to the leucine zipper domain (ZIP). Similar to 
the bZIP domain, the ZIP domain is typical for transcription factors and is important 
for DNA binding. It forms alpha helix by a periodic repetition of leucine (L) residues at 
every seventh position over a distance covering 4-8 helical turns.85 In the human and 
murine BZW2 proteins this suitable region (“L38 – L45 – L52 – L59”) is coded by 
exon 3 (Figure 6 and Figure 7). Moreover by similarity an N6-acetyllysine (K117) 
located in the putative bZIP domain was identified, as well as two C-terminal 
phosphoserines (S412, S414) (NCBI, NP_001153239.1) (Figure 6 and Figure 7). 
Thus, BZW2 possesses characteristic typical of an scafold protein placed in a 
complex, which remains to be investigated. 
 
 
Figure 7: Amino acid sequence of murine BZW2. 
The putative ZIP domain is shown in blue (L38 – L45 – L52 – L59). The following putative bZIP 
domain includes an N6-acetyllysine (K117). It consists of a basic region, shown in red (H105 – N110 – 
x9 – R120) and a leucine zipper region, shown in green (F129 – x6 – L136 – x6 – F143 – x7 – L151 – 






1.6. Aims of this study 
The current knowledge demonstrates: (1) that Wnt/β-catenin signaling is an essential 
dynamically regulated player in the developing cardiovascular system; (2) that 
activation occurs during adaptation of the cardiovascular system in response to injury 
and (3) that downregulation of β-catenin is associated with improved cardiac 
remodeling post-injury. Given the ubiquitous expression and multiple functions of β-
catenin, the identification of cell- and context-specific regulators of the pathways is 
essential for pharmacological manipulation of the cascade. Based on this knowledge, 
this work aimed to characterize cardiac specific Wnt/β-catenin components with a 
potential role on modulation of Wnt-context-dependent biological responses in the 
heart. This study specifically test the hypothesis that BZW2 is a novel cardiac Wnt/β-
catenin signaling member, and that is important for processed of cardiogenesis and 





2.1. Life organisms 
2.1.1. Mice 
Mice  Genetic Modification  Source  
NMRI Albino Animal facility UMG 
C75BL/6N  Wild type  Charles River  
Bzw2 KI 
Knock-in: causes “first knock-out”; 
insert upstream of exon 4 of Bzw2 
gene leads to expression 
interruption, resulting in truncated 
BZW2 protein 
UC DAVIS KOMPRepository 
Knockout mouse project 
Klf15 KO  
Knock-out: exon 2 of Klf15 gene is 
replaced by a non-functional LacZ 
cassette 
W. Birchmeier, Berlin; 




Inducible cardiac specific 
stabilization of β-catenin  




Inducible cardiac specific 
β-catenin knock-down  
own breading from αMhc-
MerCreMer91 (J. D. Molkentin, 
Cincinnati) and β-CatΔex2-6 
(The Jackson Laboratory) 
 
2.1.2. Cells 
Cell line Genetic background Source  
HEK293 
human embryonic kidney cells, 






MHC-Neomycin resistance cassette 
sequence (NeoR) murine ESCs; DBA 
background; hygromycin resistant 
A. M. Becker 
(L. J. Field’s Lab, 
Indianapolis)26, 93 





Puromycin resistant; C57BL/6 
background 
Stem cell technologies, 
Cat #000325  
ESC-FLAG-
BZW2 
Transgenic murine ESCs expressing 





Species Type Source  
E. coli NEB 10-beta NEB 
E. coli XL10-Gold® Ultracompetent Cells Stratagene 
 
2.2. Biological active reagents 
2.2.1. Antibodies 
Primary antibody Species Manufact. 
Dilution/Amount 
WB IF IP 
anti-β-Catenin mouse Zymed 1:1000   
anti-β-Catenin, clone 14 mouse 
BD 
Biosiences 
 1:100 - 
anti-BZW2, HPA022813 rabbit Sigma 1:1000 - 1 µg 
anti-BZW2, Q91VK1 rabbit 
Thermo 
scientific 
- 1:100 - 
anti-Caspase 3, H277 
(against procaspase-3) 
rabbit Santa Cruz 1:1000 - - 
anti-FLAG, monoclonal rabbit Sigma  1:100 - 
anti-FLAG M2, monoclonal mouse Sigma 1:1000 - 1 µg 
anti-FLAG M2, 
HRP conjugated 




1:50000 - - 
Materials 
18 
anti-HA mouse Sigma - 1:100 - 
anti-HA, HRP conjugated, 
clone HA7 
mouse Sigma 1:1000 - - 
anti-Lamin A/C goat Santa Cruz 1:200 - - 
anti-Tpt1, clone 2C4 mouse Sigma 1:1000 - - 
anti-Cardiac Troponin T, 
clone 3D6 
mouse Abcam - 1:100 - 
normal mouse IgG1 mouse Santa Cruz - 1:200 1 µg 
normal rabbit IgG rabbit Santa Cruz - 1:200 1 µg 
 
Secondary antibody Species Manufacturer 
Dilution/Amount 
WB IF 
anti-mouse-Alexa Fluor 488 goat Invitrogen - 1:200 
anti-rabbit-Alexa Fluor 594 goat Invitrogen - 1:200 
anti-goat-IgG, 
HRP conjugated 
rabbit Dako 1:5000 - 
anti-mouse-IgG, 
HRP conjugated 
rabbit Dako 1:10000 - 
anti-rabbit-IgG, 
HRP conjugated 
goat Dako 1:5000 - 
 
2.2.2. Enzymes and supplemented buffers 
Enzymes Manufacturer 
Fast AP Thermosensitive Alkaline Phosphatase 1 U/µL + 10× 
reaction buffer for AP 
Thermo Scientific 
Fast Digest Enzymes + 10× Fast Digest buffer / Fast Digest 
Green buffer 
Thermo Scientific 
GoTaq® qPCR MasterMix 2× + CXR Reference Dye Promega 





Phusion DNA Polymerase 2U/µL + 5× Phusion HF buffer Thermo Scientific 
T4 DNA Ligase 5 U/µL + 10× T4 DNA Ligase buffer Thermo Scientific 
Trypsin EDTA 0.05% / 0.25% Gibco 
Trypsin 2.5 % Gibco 
 
2.2.3. Inhibitors 
Inhibitor Dilution Manufacturer 
PhosSTOP Phosphatase Inhibitor 
Cocktail 
1 tablet / 1 ml H20 
(10×) 
Roche 
Protease Inhibitor Cocktail, Complete 
Mini EDTA free 







Novaminsulfon-ratiopharm® 500 mg/ml Tropfen Ratiopharm 
Tamoxifen  Sigma-Aldrich 
 
2.3. Media and buffers 
2.3.1. Media and supplements 
Supplement Manufacturer 
Adenosine Sigma 
L(+)-Ascorbic acid AppliChem 
Cytidine Sigma 
DMEM (+ Glucose, - Pyruvate), #61965-059 Gibco 
Materials 
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DMEM (+ Glucose, +  L-Glutamine, + HEPES, - Pyruvate), 
#42430-082 
Gibco 
Fetal bovine serum (FBS), #10270-106 Gibco 
L-Glutamin (200 mM, 100×), #25030-123 Gibco 
Guanosine Sigma 
Iscove-Medium, #F0465 Biochrom 
Leukemia inhibitory factor (LIF, 107 U/ml, ESGRO) #ESG1107 Millipore 
2-Mercaptoethanol (50 mM), #31350010 Gibco 
Non-essential amino acids solution (100×), #11140-068 Gibco 
PBS (- Ca, - Mg), #14190-169 Gibco 
Puromycin 10 mg/ml, #A11138-03 Gibco 
Penicillin-Streptomycin (100×), #15140-122 Gibco 




Medium Ingredient Volume 
HEK293 medium 
DMEM 450 ml 
FBS 50 ml 
Penicillin-Streptomycin 5 ml 
MEF medium 
DMEM 500 ml 
FBS 50 ml 
Penicillin-Streptomycin 5.5 ml 
Non-essential amino acids 5.5 ml 
mESC medium 
DMEM 500 ml 
FBS 92 ml 
Penicillin-Streptomycin 6 ml 
Materials 
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L-Glutamine 6.2 ml 
Sodium pyruvat 6.2 ml 
Non-essential amino acids  6.2 ml 
Nucleoside mix (100×): 
Adenosine 30 μM 
Guanosine 30 μM 
Cytidine 30 μM 
Uridine 30 μM 
Thymidine 10 μM 
6.2 ml 
2-Mercaptoethanol 4.34 µl 
LIF 62 µl 
mESC differentiation 
medium 
Iscove-Medium 500 ml 
FBS 120 ml 
Penicillin-Streptomycin 6 ml 
L-Glutamine 6 ml 
Non-essential amino acids 6 ml 
2-Mercaptoethanol 4.34 µl 
L(+)-Ascorbic acid (fresh added) 200 µM 
 
2.3.2. Buffers and compositions 
Protein immunoprecipitation 
Buffer Ingredient Amount/Volume 
IP-lysis buffer 
HEPES 596 mg 
NaCl 438 mg 
1.5 mM MgCl2 7 mg 
EDTA 14.6 mg 
Triton-X 100 0.5 ml 
glycerol 5 ml 
Materials 
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 Fill to 50 ml with ddH2O (pH 7.5) 
IP-lysis buffer 
+ inhibitors 
IP-lysis buffer 750 µl 
Proteinase inhibitor (10×) 150 µl  
Phosphatase inhibitor (10×) 100 µl 
 
Cell lysis 
Buffer Ingredient Amount/Volume 
Bäuerle buffer 
HEPES 2.38 g 
NaCl 10.2 g 
Glycerol 100 ml 
MgCl2 102 g 
EDTA 93 mg 
EGTA 19 mg 
NP-40 5 ml 
 Fill to 500 ml with ddH2O 
Lysis buffer 
Bäuerle buffer 750 µl 
Proteinase inhibitor (10×) 150 µl  
Phosphatase inhibitor (10×) 100 µl 
Hypertonic buffer 
HEPES 2,98 g  
KCl 0,93 g 
NaCl 4,38 g 
EDTA 0,009 g 
DTT 0,039 g 
Glycerol 25 ml 
 Fill to 250 ml with ddH2O 
Hypotonic buffer 
HEPES 0,596 g  
KCl 0,186 g 
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MgCl2 0,102 g 
EDTA 0,009 g 
DTT 0,039 g 
 Fill to 250 ml with ddH2O 
 
Polyacrylamide gel electrophoresis 
Buffer Ingredient Amount/Volume 
Laemmli buffer 
Tris HCl, pH 6.8 2 ml 
Bromphenol blue 0.5% 0.5 ml 
SDS 0.8 g 
Glycerin 100% 1 ml 
β-Mercaptoethanol 1 ml 
 Fill to 10 ml with ddH2O 
Separating gel (12%, 2×) 
ddH2O 3.3 ml 
Acrylamide 30% 4.0 ml 
Tris 1.5 M, pH 8.8 2.5 ml 
SDS 10% 0.1 ml 
APS 10% 0.1 ml 
TEMED 0.004 ml 
Stacking gel (6%, 2×) 
ddH2O 2.8 ml 
Acrylamide 30% 0.85 ml 
Tris 0.5 M, pH 6.8 1.25 ml 
SDS 10% 0.05 ml 
APS 10% 0.05 ml 
TEMED 0.005 ml 
Running buffer (10×) 
Tris base 30.3 g 
Glycine 144 g 
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SDS 10 g 
 Fill to 1 l with ddH2O 
 
Western blot 
Buffer Ingredient Amount/volume 
Blocking solution 
Milk, non-fatty dried 5% 
 Dissolved in TBST 
Transfer buffer (10×) 
Tris base 75.6 g 
Glycine 74.4 g 
SDS 15 g 
 Fill to 1 l with ddH2O 
Transfer buffer + 
Methanol 
Transfer buffer (10×) 10 ml 
Methanol 20 ml 
 Fill to 100 ml with ddH2O 
TBST  
Tris/HCl 1 M, pH 7.6 20 ml  
NaCl 5 M 33 ml 
Tween-20 1 ml 
 Fill to 1 l with ddH2O 
 
Cardiac cells isolation 
Buffer Ingredient Amount/Volume 
10× Perfusion Buffer 
pH 7.4 
NaCl 70.3 g 
KCl 11 g 
KH2PO4 0.82 g 
Na2HPO4 × 2H2O 1.1 g 
Mg2SO4 × 7H2O 3 g 
HEPES 23.83 g 
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 Fill to 1 l with ddH2O 
1× Perfusion Buffer 
NaHCO3 0.195 g 
Taurin 1.875 g 
BDM 0.5 g 
Glucose 0.5 g 
10× Perfusion Buffer 50 ml 
 Fill to 0.5 ml with ddH2O 
Digestion Buffer 
Collagenase from Clostridium 
histolyticum 
0.1 g 
100μM CaCl2 6.25 μl 
 Fill to 50 ml with 1× Perfusion Buffer 
Stopping Buffer 
FBS 5 ml 
100μM CaCl2 6.25 μl 
 Fill to 50 ml with 1× Perfusion Buffer 
 
Immunofluorescence staining 
Buffer Ingredient Percentage 
Buffer A  
BSA 0.2% 
Triton X 100 0.3% 
 Dissolved in PBS 
Buffer B  
BSA 5% 
Triton X 100 0.1% 
 Dissolved in PBS 
Buffer C  
BSA 2% 
Triton X 100 0.1% 






Buffer Ingredient Amount 
TAE buffer (50x) 
Tris base 242,2 g 
EDTA  18,6 g 
Acetic acid 57,1 g 
 
2.4. Plasmids and oligonucleotides 
2.4.1. Plasmids 
Plasmid Insert Source 
pcDNA3.1+-Flag-Klf15-Neo 
cloning source for 
pcDNA3.1+-Flag-Neo 
Noack C et al., 
201278 
pcDNA3.1+-Flag-Bzw2-Neo  
full length transcript of murine 
Bzw2, neomycin resistance 
own cloning 
pcDNA3.1+-Flag-Bzw2-∆C 

















murine Bzw2, puromycin 
resistance, mOrange cassette 
own cloning 
pcDNA3.1+-HA-Klf15 human Klf15, HA-tag 
Noack C et al., 
201278 
pcDNA3.1+-β-Cat-c-Myc murine β-catenin, c-myc-Tag 
Noack C et al., 
201278 
pcDNA3.1+-Flag-β-Cat-ΔN 
murine β-catenin without exon 
3, FLAG-tag 
Noack C et al., 
201278 
pCS2+-TCF4E-HA human Tcf4, isoform 2, HA-tag Prof. A. Hecht 
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pFOPflash negative control for pTOPflash Upstate 
pRL-CMV Renilla luciferase-reporter Promega 
pGL4.10-Bzw2-promoter 








2.4.2. Cloning primers 
Oligonucleotides were designed manually or using “Primer3web” version 4.0.0. 
freeware (http://primer3.ut.ee/) and synthetized by Eurofins Genomics. 
 
Primer Sequence (5’  3’) Characteristics 
NotI-Bzw2-fwd TTGCGGCCGCTGAATAAGCAT 
NotI, ATG was 
replaced by CTG 
Bzw2-XbaI-rev3 GGGTCTAGATTAGCTTTCTTCG XbaI 
ΔC-Bzw2-fwd AAAAGCGGCCGCTGAATAAGCATC 
NotI, ATG was 




XbaI, stop codon 
ΔN-Bzw2-fwd AAAGCGGCCGCGAGTCCAGCAGT NotI 
ΔN-Bzw2-rev GCCCTCTAGATTAGCTTTCTTCGCC XbaI, stop codon 
AvrII-Puro-fwd CTTCCTAGGTAGCCCAAGCTTA AvrII 
Puro-BstZ17I-rev GGAGTATACGTTGTTCCAGACG BstZ17I 
BstZ17I-IRES-fwd CCCGTATACCCCTTCTTGACGAGTT BstZ17I 












2.4.3. Genotyping primers 






















2.4.4. qPCR primers 
Gene 
 















































































2.5. Other chemicals and consumables 
2.5.1. Kits 
Kit Manufacturer 
Mouse ES Cell Nucleofector® Kit Lonza 
Dual-Luciferase® Reporter Assay Promega 
NucleoBond® Xtra Maxi 
Macherey-Nagel 
NucleoSpin® Gel and PCR Clean-up 
NucleoSpin® Plasmid (NoLid) 
NucleoSpin® RNA 
NucleoSpin® RNA Midi 
NucleoSpin® Tissue 




GeneRuler 1 kb DNA Ladder 
Thermo Scientific 
GeneRuler 100 bp DNA Ladder 
MassRuler DNA Ladder Mix 
6× Loading Dye 





2.5.3. Other chemicals 
Substance Manufacturer 
Acetic acid 100% Merck 
Acrylamide 30% AppliChem 
Agarose UltraPureTM AppliChem 
Ammonium persulfate (APS) Life technologies 
Ampicillin AppliChem 
2,3-BDM Sigma Aldrich 
Bromophenol blue AppliChem 
BSA (bovine serum albumin) Sigma-Aldrich 
Bradford reagent, Rothi-Quant Roth 
Calcium chloride Roth 
Chemoluminescence reagent (Femto Lucent) G Biosciences 




DMSO Thermo Scientific 
DSP Thermo Scientific 
dNTP PCR Nucleotide-Mix (10 mM)  Promega 
DTT 100mM  Promega 
EDTA AppliChem 
EGTA AppliChem 
Ethanol Carl Roth 







HEPES, ultrapure Carl Roth 
Roti®-Histofix 4 % Carl Roth 
Hoechst Life technologies 
LB Agar / LB Medium   AppliChem 
Magnesium chloride AppliChem 
β-Mercaptoethanol AppliChem 
Methanol  Carl Roth 
Milk, non-fatty dried Carl Roth 
Moviol® Carl Roth 
NP-40 Sigma 
Poly-L-lysine Sigma 
Ponceau S AppliChem 
Potassium chloride Carl Roth 
2-Propanol  AppliChem 
Protein G Sepharose 4 Fast Flow GE Healthcare 
SDS (Sodiumdodecylsulfat) AppliChem 
Sodium chloride Carl Roth 
TEMED (N,N,N‘,N‘-Tetramethylethylendiamin) AppliChem 
Toluene Roth 
TransFectin Bio Rad 
Tris Base, ultrapure  Carl Roth 
Tris-hydrochloride Carl Roth 
TritonX-100 AppliChem 
TurboFect Thermo Scientific 




2.6. Devices and software 
2.6.1. Devices 
Device Manufacturer 
7900 HT Fast Real-Time PCR System Applied Biosystems 
Beckman J2-21 Floor Model Centrifuge Beckman 
CASY cell counter Model TT Roche Innovatis AG 
Centrifuge 5417 C/R Eppendorf 
Electrophoresis chamber PerfectBlue™Maxi L Peqlab 
Electroporator Nucleofector™ 2b Device Lonza 
FlexStation 3 Multi-Mode Microplate Reader Molecular Devices 
Fully Automated Rotary Microtome Leica RM2255 Leica-Biosystems 
GelDocTM XR Imaging System BioRad 
Heated Paraffin Embedding Module Leica EG1150 H Leica-Biosystems 
Heraguard™ ECO Clean bench Thermo Scientific 
Incubation Hood Certomat® HK for Orbital Shaker 
B.Braun Biotech 
International 
Ismatec REGLO ISM834 Digital 4-Ch Var-Speed Pump Ismatec 
Low Voltage Power Supply Power Pack P25 Biometra 
Luminometer GLOMAXTM 96 Microplate Promega 
Microscope Axio Imager M2 Carl Zeiss 
Microscope Axiovert 200 Carl Zeiss 
Microscope Leica M80 Leica 
Microscope LSM 710 Carl Zeiss 
Microscope Stemi 2000 Stereo Carl Zeiss 
SteREO Lumar V12 with Microinjection Carl Zeiss 
MIR-153 Refrigerated Incubator Sanyo 
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Orbital Shaker Certomat® U 
B.Braun Biotech 
International 
Spectrophotometer NanoDrop 1000 Peqlab 
T Gradient Thermocycler Biometra 
Thermomixer Compact Eppendorf 
TissueLyser II Quiagen 
UV Transilluminators TI1 Biometra 
Veriti® 96-Well Thermal Cycler Applied Biosystems 
VersaDocTM Imaging System BioRad 
2.6.2. Software 
Software Manufacturer 
AxioVision Carl Zeiss 
Gentle V1.9.4 Magnus Manske, Köln 
GLOWMAX 1.9.2 Promega 
GraphPad Prism 4 GraphPad Software 
Image Lab Bio Rad 
ND-1000 V3.8.1 NanoDrop Technologies 
SDS 2.4 Applied Biosystems 
Soft Max Pro5.4 Molecular Devices 
Quantity One 4.6.7 Bio Rad 
VisiView Version 2.1.1 Visitron Systems GmbH 





3.1. Molecular biological methods 
3.1.1. Cloning overview 
pcDNA3.1+-flag-Bzw2-Neo: Complementary DNA (cDNA) synthetized from extracted 
RNA from murine cardiac tissue by reverse transcription was used to generate Bzw2 
transcript including restriction digestion sites via PCR. The Bzw2 transcript was 
cloned into pcDNA3.1+-flag-Klf15-Neo plasmid replacing Klf15 transcript. 
pcDNA3.1+-Flag-Bzw2-∆C/∆N: Flag-tagged truncated forms of Bzw2 transcript were 
synthetized using pcDNA3.1+-flag-Bzw2-Neo plasmid. 
pcDNA3.1+-Flag-Bzw2-Hygro: Bzw2 expressing plasmids with different resistance 
cassettes were generated. Hygromycin resistance cassette was cut from pLVX-Tet-
On Advanced vector and cloned into pcDNA3.1+-flag-Bzw2-Neo vector replacing 
neomycin resistance cassette. 
pcDNA3.1+-Flag-Bzw2-Puro: Puromycin resistance cassette including restriction sites 
was synthetized using pLVX-Tight-Puro vector via PCR and cloned into pcDNA3.1+-
Flag-Bzw2-Hygro plasmid replacing hygromycin resistance cassette. 
pcDNA3.1+-Flag-Bzw2-Puro-Orange: IRES-mOrange cassette including restriction 
site was synthetized using pBSK-aMHC-NIOIL plasmid and cloned into pcDNA3.1+-
Flag-Bzw2-Puro plasmid downstream of puromycin resistance cassette. This cloning 
step was done to simplify positive clones screening. However expression of the 
mOrange fluorescent protein chromophore did not work. 
pGL4.10-Bzw2-promoter: A putative Bzw2 promoter region (a sequences 1745 bp 
upstream the Bzw2 start codon including 3 TCF/LEF putative consensus sequences) 
including restriction digestion sites was synthetized from genomic DNA extracted 
from murine tissue and cloned into the multiple cloning site of pGL4.10 vector 
generating pGL4.10-Bzw2-promoter plasmid. 
3.1.2. DNA and RNA extraction 
Genomic DNA, RNA and plasmid DNA were extracted from murine and human tissue 
and cells using commercial Macherey-Nagel kits accordingly manufacturer’s 
instruction. Quantification was done using NanoDrop photometer. 
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3.1.3. Polymerase chain reaction 
Polymerase chain reaction (PCR) was used to amplify and modify specific DNA 
sequences for cloning. Therefore, specific modified primers were designed. The copy 
accuracy was ensured by the proof reading function of Phusion polymerase (Thermo 
Scientific). Amounts of enzyme, primers, dNTPs and DNA as well as PCR program 
were taken accordingly manufacturer’s instruction. “Tm calculator” freeware from 
New England Biolabs or gradient PCR were used to identify the optimal annealing 
temperature. Extension time was taken 1 min per 1 kb DNA. 
3.1.4. Enzymatic digestion, dephosphorylation and ligation of DNA 
Enzymatic digestion (FastDigest enzymes from Thermo Scientific) was used to test 
plasmids as well as to generate appropriate binding sites in target DNA and in 
vectors for further ligation. Dephosphorylation (Fast AP Thermosensitive Alkaline 
Phosphatase from Thermo Scientific) avoided re-ligation of vectors. Ligation of 
vectors (40 ng) with target DNA (1:7 mol ratio) was done using T4 DNA Ligase (from 
Thermo Scientific). After Ligase inactivation new generated plasmids were 
transformed into E. coli for multiplication. All steps were done accordingly 
manufacturer’s instruction. 
3.1.5. DNA transformation into Escherichia coli 
50 µl of Escherichia coli (E. coli) were thawed on ice. 2 µl of inactive ligation reaction 
or ~10 ng of plasmid DNA were mixed to E. coli and incubated on ice for 30 min. 
After heat shock at 42°C for 45 s cells rested on ice for 5 min. Next, 400 µl of LB 
medium were added and cells incubated at 37°C for 30 min at 300 rpm. Afterwards 
cells were plated on LB agarose plates (100 µg/ml ampicillin). 
3.1.6. Agarose gel electrophoresis 
Agarose gel electrophoresis was used for visualization and separation of DNA 
fragments, using TAE buffer and agarose gel consisting of 0.5-2% agarose and 
0.001% ethidium bromide. 
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3.1.7. Sequencing of DNA 
DNA sequencing was done by Sequence Laboratory Göttingen using standard 
primers (T7 / CMV-fwd / BGH-rev / M13-rev for pcDNA3.1+ and RV3 for pGL4.10) or 
cloning primers. 
3.1.8. Reverse transcription PCR 
For RNA expression analysis cDNA was synthesized by reverse transcription PCR 
(RT-PCR) using 0.4-1 µg mRNA, 500 µg oligo-dT as primers, 10 pmol dNTPs (from 
Promega), M-MLV 5X Reaction Buffer and 100 units of RNA-dependent DNA 
polymerase Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT from 
Promega) in 20 µl total volume. Negative RT (no enzyme) was used as control for 
genomic DNA contamination. The method was done accordingly manufacturer’s 
instruction. 
3.1.9. Quantitative real-time PCR 
Quantitative real-time PCR (qPCR) allows quantification of RNA expression in tissue 
and cells using cDNA as template for polymerase chain reaction. SYBR Green™ dye 
intercalates into double-stranded DNA with each cycle. Using the standard curve of 
gene of interest with known concentration (103-108 molecules/µl) the quantity of 
expressed RNA of interest can be evaluated. qPCR was done using GoTaq® qPCR 
MasterMix (from Promega) in 7900 HT Fast Real-Time PCR System (from Applied 
Biosystems) according to the PCR program below (Table 1) and was analyzed by 
SDS2.4 software (Applied Biosystems). cDNA was used in 1:1 – 1:10 dilutions 
depending on mRNA amount. 
   Table 1: qPCR program. 
Cycle step Temp. Time Cycles 
 50°C 2 min 
1× 
Initial denaturation 95°C 10 min 
Denaturation 95°C 15 sec 
40× Annealing 55/60°C 1 min 
Extension 95°C 15 sec 
Final extension 60°C 15 sec 
1× 




3.2. Biochemical methods 
3.2.1. Protein extraction 
For protein extraction, tissue or cells were first washed with PBS, subsequently 0.3-1 
ml of protein lysis buffer was added. All steps were done on ice. Cells were scrapped 
from the surface, placed in Eppendorf tubes and mixed by pipetting up and down. 
Alternatively, tissue was placed in 2 ml Eppendorf tubes with protein lysis buffer and 
metal beads and further disrupted and homogenized for 1.5 min at 30 Hz by 
TissueLyser (Qiagen). Next, the lysates were centrifuged at 1000 × g for 20 min at 
4°C. The supernatants were taken and protein concentration was quantified by 
Bradford assay using bovine serum albumin (BSA) as a standard curve. Protein 
lysates were stored at -20°C. 
3.2.2. Protein fractionation 
Protein separation in cytosolic and nuclear fractions was done using hyper- and 
hypotonic buffers. The lysis of tissue and cells was done as described in 3.2.1 till the 
centrifugation step, using 0.3-1 ml of the Hypotonic buffer instead of the lysis buffer. 
The protein lysates from tissue were placed in new 1.5 ml tubes without beads. After 
incubation on ice for 15 min, pre-diluted nonoxinol 40 (10% NP-40) was added to the 
final concentration of 1% for tissue and 0.1% for cells. Lysates were vortexed and 
incubated for 5 min on ice and centrifuged at 4,000 rpm for 5 min at 4°C. The 
supernatant with the cytosolic protein fraction was taken and frozen for storage at -
20°C. The rest supernatant was completely removed from the pellet with the nuclear 
fraction. The pellet was dissolved in 0.3 ml of the Hypertonic buffer and incubated for 
25 min on ice. Next, NP-40 was added to the final concentration of 1% for tissue and 
0.1% for cells. Lysates were vortexed and incubated for 10 min on ice and 
centrifuged at 13,000 rpm for 5 min at 4°C. The supernatant with the nuclear protein 
fraction was taken and frozen for storage at -20°C. 
3.2.3. Co-Immunoprecipitation 
Co-Immunoprecipitation (co-IP) was used to test an interaction between two proteins, 
where one of the proteins was immunoprecipitated from protein lysate bound on its 
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interacting partners. The precipitate was subsequently analyzed by Western blot 
assay or mass spectrometry regarding the interactor of interest. Co-IP was prepared 
in vivo with BZW2 as precipitated protein and β-catenin as a potential interactor 
which was subsequently detected by Western blot assay. For in vitro co-IP Flag-
Bzw2 construct was co-transfected with HA-Klf15 into human embryonic kidney cells 
(HEK293). BZW2 was immunoprecipitated using antibodies against FLAG-tag and 
KLF15 was detected by Western blot assay using antibodies against HA-tag. 
Appropriated immunoglobulin G (IgG) instead of antibody of interest served as a 
negative control. Co-IP was always done from fresh isolated protein lysates. 
3.2.3.1. Co-IP in vivo 
Murine heart was isolated, washed with PBS and cut in ~2 mm small pieces. To 
crosslink interacting proteins tissue was placed into a 2 ml tube and incubated for 30 
min at room temperature (RT) in 2 mM DSP/PBS (Lomant's Reagent from Thermo 
Scientific) which was pre-dissolved in DMSO accordingly manufacturer’s instruction. 
Next, tissue was washed with PBS and after adding IP-lysis buffer grinded with 
mortar and pestle. Lysate was centrifuged at 100 × g for 10 min at 4°C. After 
collecting the supernatant, centrifugation and collecting were repeated. Lysate was 
never vortexed! Finally, the protein concentration was measured. To avoid unspecific 
precipitation, lysate was pre-cleaned with sepharose beads (Protein G Sepharose 4 
Fast Flow from GE Healthcare). For that, after washing 3 times in PBS, 100 µl beads 
were added to 1-4 µg of protein (total, including negative control portion) in a 1.5 ml 
tube. The lysate with beads was filled with PBS to ~1 ml and was incubated for 1 h at 
4°C by rotation. To remove beads, lysate was centrifuged at 100 × g for 1 min at 4°C. 
The lysate was collected and separated in 2 equal parts. 1 µg of rabbit-anti-BZW2 
antibody (from Sigma Aldrich) as well as 1 µg rabbit-IgG (from Santa Cruz) as a 
negative control were added to one lysate part. The protein-antibody mix was 
incubated over night at 4°C by rotation. Next, pre-washed 50 µl sepharose beads 
were added to each condition. The protein-antibody-beads mix was incubated for 1.5 
h at 4°C by rotation. Finally sepharose beads were carefully washed 3 times in PBS 
by centrifugation at 100 × g for 1 min. To elute proteins from beads, PBS was 
completely removed and beads were incubated in 40 µl of 4× Laemmli buffer per 
condition for 5 min at 95°C. After it cooled down it was centrifuged for 1 min at 1000 
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× g and 30 µl of each eluate were collected. The eluate was stored at -20°C for 
further analysis. 
3.2.3.2. Co-IP in vitro 
HEK293 cells were co-transfected with plasmid expressing FLAG-BZW2 and plasmid 
expressing HA-KLF15 (transfection protocol see 3.4.3.). After 2 days in culture cells 
were washed with PBS and lysed by adding 1 ml of IP-lysis buffer per 10 cm dish 
plate and collected by scrapping. The lysate was carefully pipetted up and down and 
centrifuged at 100 × g for 20 min at 4°C. The protein concentration was measured by 
Bradford assay. Apart from the used antibodies, same procedure, as written above in 
3.2.3.1., was used from this step on. Here immunoprecipitation was done using 
mouse-anti-FLAG antibody (Sigma) and mouse-IgG (Santa Cruz) for negative 
control. 
3.2.4. Mass spectrometry 
Nanoflow liquid chromatography tandem mass spectrometry (LC-MS/MS) was done 
at the Proteomics Facility of the UMG (Head: Prof. H. Urlaub / Dr. C. Lenz). Shortly, 
BZW2 protein enriched by IP from murine heart tissue using rabbit-anti-BZW2 
antibody and rabbit-IgG as a negative control (see 3.2.3.1.) was separated by one-
dimensional PAGE and stained with colloidal Coomassie. Each lane was cut into 23 
slices, reduced, alkylated, subjected to digestion with trypsin and analyzed by LC-
coupled-MS/MS on an Orbitrap XL mass spectrometer. Affinity co-purified proteins 
are categorized as specific or non-specific according to the relative abundance of the 
protein in bait vs. control. Specific interaction partners are significantly more 
abundant in the purified sample containing the bait than in a control sample (IgG 
isotype).94, 95 The resulting MS/MS spectra were searched against the NCBI protein 
database for protein identification. Analysis was done using the Mascot software 
(Matrix Science). 
3.2.5. Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
separate proteins from a protein lysate according to their molecular mass. Negatively 
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charged SDS binds to proteins and leads to their repulsion of each other. First, 
quantified and denatured protein lysates (5 min at 95°C in 4× Laemmli buffer) were 
loaded on the collecting gel. Collecting was done at 70 V by constant electric current. 
The separation started in the following separation gel where smaller proteins migrate 
faster, so that proteins were separated linear their molecular mass in the gel (140 V 
by constant electric current). 
3.2.6. Western blot assay 
By Western blot assay (WB) proteins were transferred from the SDS polyacrylamide 
gel to polyvinylidene fluoride (PVDF) membrane in a vertical electric field at 140 mA 
by constant voltage. Proteins stayed on the membrane by hydrophobic polar 
interactions and were immunodetected using specific antibodies. The specific primary 
antibodies were either directly bound to the enzyme peroxidase or secondary 
antibodies were needed. By substrate adding peroxidase reduces hydrogen 
peroxide, this oxides luminol under formation of chemiluminescence. The 
chemiluminescence was detected by VersaDocTM XR Imaging System. The 
normalized density (analyzed using Quantity One 4.6.7 or Image Lab from BioRad) 
was compared between different samples. 
3.2.7. Luciferase reporter assay 
Luciferase reporter assay was used for two different aims. 
 
To test for a possible role of BZW2 in the regulation of Wnt/β-catenin signaling 
activity, TOPflash/FOPflash luciferase reporter assay was used. A TOPflash plasmid 
(from Upstate) includes luciferase gene driven by a TK promoter containing 3 
TCF/LEF binding sites, the target genes of Wnt/β-catenin signaling. TOPflash 
plasmid was co-transfected (transfection protocol see 3.4.3., Page 44) with an empty 
vector as a control and with a vector including a potential regulator like BZW2 into 
HEK293 cells. After culturing for 2 days cells were lysed by a passive lysis buffer 
accordingly manufacturer’s instruction (Dual-Luciferase® Reporter Assay from 
Promega). Measuring of luminescence was done after adding the substrate (luciferin) 
via GLOMAXTM 96 Microplate luminometer from Promega. As a negative control 
FOPflash plasmid was used including 3 mutated TCF/LEF binding sites. To consider 
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transfection efficiency, Renilla plasmid (pRL-CMV from Promega) was co-transfected 
and Renilla luciferase activity was used for normalization. 
To test for a possible role of the Wnt/β-catenin signaling in regulation of 
transcriptional activity of Bzw2, a putative promoter region of Bzw2 (1745 bp 
upstream from ATG) including 3 putative TCF/LEF binding sites was cloned into a 
plasmid for driving a luciferase gene (pGL4.10 from Promega). The empty plasmid 
was used as a control. Renilla expressing plasmid was co-transfected and Renilla 
luciferase activity was used for normalization. 
3.3 Immunofluorescence staining 
3.3.1. Immunocytochemistry 
Immunofluorescence (IF) staining of cells was used to detected protein expression in 
cultured cells. Therefore, cells grown on glass cover slips were washed with PBS 3 
times for 2 min, fixed with Histofix for 30 min at RT and washed again with PBS 3 
times for 2 min. Next, cells were permeabilized with 0.3% Triton X-100, 0.2% BSA in 
PBS for 10 min at RT and blocked with 5% BSA, 0.1% Triton X-100 in PBS for 1 h at 
RT. Afterwards, cells were incubated with primary antibodies in 1% BSA, 0.1% Triton 
X-100 in PBS over night at 4°C. Therefor cover slips with cells were placed on 50 µl 
drops of antibody solution inverted in a dark chamber. Next day, cells were washed 
with PBS 3 times for 10 min and incubated with the secondary antibodies for 1 h at 
RT in the same way as the primary antibodies. After washing in PBS 3 times for 10 
min, cells were incubated with Hoechst solution (1 µg/µl final concentration) in PBS 
for 5 min at RT to stain cell nuclei. Then, cells were washed again 3 times for 5 min 
and the cover slips were put on the microscope slides inverted on 20 µl drops of 
Mowiol. Cells were stored at 4°C and were observed under fluorescence microscope 
24 h after mounting. 
3.3.2. Immunohistochemistry 
Immunofluorescence (IF) staining of murine tissue was used to detected protein 
expression in the heart. Murine hearts were isolated, washed in PBS and fixed in 
Histofix overnight at 4°C by rotation. Next, tissue was washed again with PBS and 
incubated in 70% ethanol solution at 4°C at least for 3 days. Tissue embedding and 
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slides cutting were performed by technical assistant Ines Müller. For embedding 
hearts were dehydrated in a row of ethanol (80% for 30 min, 90% for 30 min, 96% for 
1 h, 96% for 30 min, 100% for 1 h and 100% for 30 min of ethanol). After incubation 
in 1:1 mixture of ethanol/toluene for 15 min, 1 h incubation in toluene and further 
incubation for 30 min in toluene, hearts were embedded overnight in paraffin at 60°C. 
Serial 4 μm slides were cut and stored for further use at 4°C. 
Preparation of paraffin slides for staining was performed by technical assistant Ines 
Müller. Paraffin slides were first deparaffinized in xylol / Roti-Histol for 10 min and 
rehydrated in an ethanol row twice for each step for 2 min: 100%, 95%, 90%, 80%, 
70% ethanol. Next, slides were washed in water for 10 min, in PBS for 10 min and 
then incubated in 10 mM trisodium citrate, 0.05% Tween20 buffer (pH 6) in a 
microwave at 180 W for 15 min. Afterwards slides were cooled down for 20 min at 
RT, washed with PBS for 5 min, blocked in 5% BSA, 0.1% Triton X-100 in PBS for 1 
h at RT in a dark wet chamber and incubated there with primary antibodies in 1% 
BSA, 0.1% Triton X-100 in PBS overnight at 4°C. On the second day, slides were 
washed with PBS 3 times for 5 min, incubated with secondary antibodies for 1 h at 
RT in a dark wet chamber, washed with PBS 3 times, incubated with DAPI (1:1000) 
in PBS for 10 min at RT to stain cell nuclei and washed again 3 times. Afterwards 
slides were mounted with Mowiol® and air dried. Slides were stored at 4°C. 
3.4. Cell work 
3.4.1. Thawing and freezing of cells 
Cells were harvested as explained in 3.4.2. (Page 44) and 3.4.4. (Page 44), counted, 
centrifuged for 5 min at 300 × g and diluted in freezing medium to 1.5×106 cells per 1 
ml medium. 1 ml of cells was placed per 1 cryo tube. Tubes were placed in an 
isopropanol container and were slowly frozen at -80°C. After one day cells were 
placed for storage at –150°C or in liquid nitrogen. For thawing, cells were quickly 
transferred to appropriate 37°C-warm medium and platted as described in 3.4.2. and 
3.4.4. On the second day medium was changed. 
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3.4.2. Culture of HEK293 cells 
Human embryonic kidney cells (HEK293) were used as a standard in vitro model for 
validation of protein interaction, protein regulative capacity analysis as well as for 
characterization of protein localization in cell compartments. Cells were cultured in 10 
ml medium in T75 flasks at 37°C and 5% CO2. For splitting, medium was removed 
and cells were incubated with 4 ml 0.25% trypsin for 3-5 min at 37°C. Digestion was 
stopped by adding 8 ml of medium. Cells were pipetted up and down for 3-4 times for 
better cell separation. 2 ml of cells was mixed with 8 ml medium and placed into a 
new flask. HEK293 cells were splitted two times per week. 
3.4.3. Transient transfection of HEK293 
Cells were harvested as explained in 3.4.2. (Page 44), counted and plated on 1% 
collagen pre-coated plates (Table 2). For plating on glass cover slips for a following 
cell staining, pre-coating was done with poly-L-lysine. Therefore poly-L-lysine was 
incubated on the glass cover slips at 37°C for 2 min, than it was removed and cover 
slips were air dried. Next day, a transfection mix prepared according to the product 
manual (Transfectin or Turbofect) was added to the medium of cells. After 4-6 h 
medium was changed and cells were cultured for 2 days for the following analysis. 
   Table 2: Seeding HEK293 cell number. 
Plate format 
Cell number per plate 
/ well for seeding 
10 cm dish 2.2×106 
6-well plate 3×105 
12-well plate 105 
24-well plate 5×104 
3.4.4. Culture of mESCs 
The used murine embryonic stem cell line was published elsewhere.26 The cells were 
isolated in L. J. Field’s Lab (Indianapolis) from morula of transgenic mice expressing 
enhanced green fluorescence protein (EGFP) under control of alpha-myosin heavy 
chain (α-Mhc, a cardiac muscle specific factor) promoter as well as geneticin (G-418) 
resistance protein under the α-Mhc promoter. These characteristics allow selection 
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and visualization of cardiomyocytes during differentiation of ESCs. Cells were 
cultured in 10 ml of ESC-medium at 37°C and 5% CO2 on irradiated, inactivated 
murine embryonic fibroblasts (MEFs), plated on a 0.1% gelatin coated 10 cm dish at 
least one day before seeding ESCs. For splitting, cells were washed with 5 ml of pre-
warmed PBS and incubated with 4 ml 0.25% trypsin for 3-5 min at 37°C. Digestion 
was stopped by adding 8 ml medium. Cells were pipetted up and down for 3-4 times 
for better cell separation. 106 cells were taken in 10 ml medium and placed into a 
new 10 cm dish (Table 3). ESCs cells were splitted every two days; the medium was 
changed on the day between including washing with PBS. 
 Table 3: Seeding ESC number. 
Plate format 
MEF number per plate 
/ well for seeding 
ESC number per plate 
/ well for seeding 
10 cm dish 2×106 1×106 
6-well plate 2.5×105 1.25×105 
12-well plate 105 5×104 
24-well plate 5×104 2.5×104 
96-well plate 2.6×104 uncounted 
3.4.5. Generation of transgenic mESC line 
ESCs were used to analyze gain-of-function of BZW2 during cardiogenesis in vitro. 
For that, a new transgenic BZW2 overexpressing ESC line was generated. The 
overexpressing construct (pcDNA3.1+-Flag-Bzw2-Puro-Orange) included the coding 
sequence (CDS) of the murine BZW2 transcript tagged by FLAG and driven by a 
cytomegalovirus (CMV) promoter as well as the puromycin resistance gene driven by 
a simian-virus (SV40) promoter. Transfection of the construct occurred by a 
nucleofection using Amaxa® Nucleofector® Technology (from Lonza). The construct 
was cut from the plasmid by SalI digesting enzyme, separated by agarose gel 
electrophoresis and extracted from the gel. On the splitting day cells were fed with 
ESC medium. Four hours later MEFs were removed from the culture by pre-plating. 
Therefore, cells were collected as described in 3.4.4. (Page 44) and incubated on the 
same plate for 30 min at 37°C. The supernatant was collected and cells were 
counted. The following protocol was done according to manufacturer’s instruction; 
1.5×106 cells, 2 µg of DNA and A-23 program were used. Afterwards transfected 
cells were plated on a 10 cm dish. On the second day medium was changed. On the 
Methods 
46 
third day clones were started to be selected by puromycin (1 µg/ml final 
concentration) for 12 days. Next, 96 clones were picked and placed on a 96-well 
plate. After medium change and two days of culture clones were separated by 
trypsinization with 50 µl 0.25% trypsin, following stop of trypsinization with 100 µl 
medium and pipetting up and down. On the next day 1/4-1/2 cells (depending on the 
density) per clone were splitted on a new 96-well plate for DNA extraction and 1/4-1/2 
on a new 96-well plate with a MEF layer for freezing and storage. On the next day 
cells for freezing were trypsinized with 25 µl trypsin, stopped with 75 µl ESC medium 
and mixed with 100 µl ESC medium & freezing medium in the ration 1:1. 30 µl 
mineral oil were added on top to cover the cells. The plate was sealed with paraffin 
and put in a Styrofoam box at -80°C for storage. Cells for DNA extraction were 
washed with PBS. DNA extraction was done with a Macherey-Nagel Kit. The 
genotyping of clones was done using REDExtract-N-Amp Tissue Kit (from Sigma) 
accordingly manufacturer’s instruction (see 3.5.2., Page 48). 100 ng DNA and 400 
nM of each primer (CMV-mBzw2ex3-4-fwd / -rev) were used. After identification of 29 
DNA-positive clones, they were plated on a new 96-well plate. Next, they were 
splitted 1/6-1/2 cells per clone on 24-well plates for further RNA extraction and on a 
new 96-well plate for further culture. RNA was extracted using a Macherey-Nagel Kit. 
RNA expressed from the construct as well as the total Bzw2 RNA (including 
endogenous Bzw2) was analyzed by qPCR. After clone selection cells were seeded 
on 6-well plates without the MEF layer for subsequent protein extraction and 
analysis. 
3.4.6. Differentiation of mESCs to cardiomyocytes 
Two identified BZW2 overexpressing ESC clones (#15, #34) and untransfected cells 
(WT) as negative control were used in differentiation experiment. Spontaneous 
cardiomyocyte differentiation was used (Figure 8). On differentiation day 0 cells were 
plated as described before, washed with PBS and collected in differentiation medium 
(2.5×104 cells/ml). Next, 200 hanging drops per cell line, each drop 20 µl, were 
prepared on the lid of two 15 cm dishes. 10 ml of PBS per dish prevented drying-out 
of drops. On differentiation day 3 hanging drops including formed embryoid bodies 
(EBs) were collected with 10 ml differentiation medium per cell line in low attachment 
dishes. On differentiation day 5 EBs were plated on gelatin coated plates: 6-well 
plates for protein analysis, 12 well plates for RNA analysis, 96-well plates for 
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monitoring of GFP expression and beating areas. On differentiation day 11 
cardiomyocytes selection with G418 (1 mg/ml final concentration) started. Samples 
for protein analysis were collected on differentiation days 0 and 16, for RNA analysis 
on days 0, 4, 9 and 16. The size of EBs were measured on day 3 and 5, GFP and 
beating areas were monitored on differentiation day 7, 9, 11, 13 and 16. 
 
 
Figure 8: The workflow of the differentiation experiments. 
The scheme describes the workflow of the differentiation experiments of ESCs to cardiomyocytes (see 
text above). Modified from Renger A et al., 2013.
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3.4.7. Isolation of cardiac cells 
Cardiomyocytes and cardiac fibroblasts were isolated via Langendorff preparation 
from murine hearts with the help of Eric Schoger und Sebastian Pasch. The heart 
was dissected including remaining aorta from sacrificed mice. It was washed in cold 
PBS, transferred into 1× Perfusion Buffer and placed on a blunt 20G cannula. The 
heart was fixed on the cannula with yarn on remaining aorta and fixed on the 
Langendorff apparatus and perfused with Perfusion Buffer for 1 min. The following 
digestion was performed by perfusion with Digestion Buffer for 9 min at 37°C. Heart 
was separated from atria, remaining aorta and cannula and was transferred in the 
Digestion Buffer. The tissue was minced. After adding of 5 ml Stopping Buffer 
suspension was re-suspended and collected in a 15 ml reaction tube. It was filled up 
to a total volume of 10 ml with Stopping Buffer and was set for 2 min to separate cell 
debris. Supernatant was collected, set for 8 min and transferred to a new 15 ml 
collection tube. Remaining pellet was re-suspended in 10 ml Stopping Buffer and set 
for 8 min, supernatant was collected. Remaining Pellet was re-suspended in 10 ml 
Stopping Buffer a second time and set for further 8 min, supernatant was collected. 
Cardiomyocytes containing pellet was shock frozen in liquid nitrogen or immediately 
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used for RNA extraction. Supernatant was centrifuged at 300 × g for 5 min at 4°C 
and removed, while the pellet was collected in 10 ml MEF Medium and pre-plated in 
a 100 mm culture dish. After 2 h medium was changed. After 2 d medium was 
changed a second time. On day three, fibroblast medium was removed, fibroblasts 
were rinsed in PBS and trypsinized. After re-suspension, cells were placed into 15 ml 
reaction tubes and centrifuged at 300 × g for 5 min at 4°C. Supernatant was removed 
and pellet was shock frozen or used for RNA extraction. 
Cardiac progenitor cells were isolated by Dr. Maria Patapia Zafeiriou as described in 
Zafiriou MP et al., 2014.96 
3.5. Mice 
All mouse experiments were approved by the animal review board LAVES 
(Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit). 
3.5.1. Organ removal 
Mice were shortly anesthetized by isoflurane inhalation. Cervical dislocation followed 
directly. The organs were removed, washed in cold PBS and prepared for next steps. 
3.5.2. Genotyping 
Genotyping of mice was done using REDExtract-N-Amp Tissue PCR Kit from tail tips 
biopsies (~18 days after birth) accordingly manufacturer’s instruction. The used 
primers were “NeoR-F and Bzw2tt-R” for the Bzw2 KI mice and “Bzw2-F and Bzw2tt-
R” for the wild type. Per sample to 5 µl of PCR Mix 4 pmol s1-, 4 pmol s2- and 8 pmol 
as-primer were added. Additionally 2 µl genomic DNA from a tail tip, extracted using 
the same kit, was added and filled to total 10 µl with H2O. PCR program as described 
in Table 4 was used. Genotyping was done with help of technical assistants Ursula 




   Table 4: Genotyping PCR program. 
Cycle step Temp. Time Cycles 
Initial denaturation 94°C 300 s 1× 
Denaturation 94°C 15 s 
40× Annealing 54°C 30 s 
Extension 72°C 60 s 
Final extension 72°C 300 s 1× 
3.5.3. Transverse aortic constriction (TAC) operations 
Transverse aortic constriction (TAC) was used as an experimental model for 
pressure overload-induced cardiac hypertrophy. Constriction of the aorta occurred in 
the area of the aortic arch between the brachiocephalic artery and the left common 
carotid artery (Figure 9). Surgical intervention (Sham) served as negative control. 
Operations were done by Sabrina Wollborn, service unit SFB 1002. Heterozygous 
mice (20 TAC, 10 Sham) as well as wild type mice (20 TAC, 10 Sham) of mixed 
gender (1:1) were operated at the age of approximately 14 weeks. The cardiac 
function was analyzed by echocardiography two weeks before the operation as well 
as two and four weeks after the operation. Cardiac tissue was collected five weeks 
after TAC. 
 
Figure 9: Transverse aortic constriction (TAC) in mice. 
Transverse aortic constriction (TAC) between the brachiocephalic artery and the left common carotid 
artery leads to a pressure overload in the heart in systole, which induces compensated cardiac 
hypertrophy with the following cardiac dilatation and heart failure. 




Analysis of cardiac function in mice was done by echocardiography, performed by the 
service unit SFB 1002. Mice were anesthetized by isoflurane inhalation and 
ventricular measurements were done using the VisualSonics Vevo 2100 Imaging 
System equipped with a 45 MHz MS-550D MicroScan transducer by Marcel Zoremba 
and Roland Blume. Analyses of the raw echocardiography data were done by Beate 
Knocke. Following parameters were measured in systole (-s) and in diastole (-d), 
apart from epicardium area (Epi, only in systole): anterior (AWTh) and posterior 
(PWTh) wall thickness, LV interior length (L) and LV interior area (Area) as shown in 
Figure 10. Heart weight (HW), fraction area shortening (FAS) and ejection fraction 
(EF) were calculated using following formulas: 
HW = 1.05 × 5/6 × Epi-s × (L-s + (AWTh-s + PWTh-s)/2) – Area-s × L-s  
FAS = (Area-d – Area-s) / Area-d × 100 
EF = (Vol-d – Vol-s) / Vol-d × 100 
Vol = 5/6 × Area × L 
 
 
Figure 10: Echocardiography analysis. 
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Echocardiography analyses were performed by the service unit SFB 1002. A Parasternal long axis 
view of the heart, showing LV, RV, LA and aorta ascendens; L: LV interior length. B Parasternal short 
axis view of the heart, showing LV, RV and epicardium; AWTh: anterior wall thickness; PWTh: 
posterior wall thickness; Area: LV interior area; Epi: epicardium area. 
Schematic images are modified from Patrick J. Lynch, medical illustrator. 
3.5.5. Statistical analysis 
Statistical significance between two groups was analyzed by Student’s t-test, using 
GraphPad Prism4 program. P values smaller than 0.05 were taken as significant 
(*p<0.05; **p<0.01; ***p<0.001). Results were shown as arithmetic mean with 





4.1. Molecular characterization of BZW2 
4.1.1. Validation of BZW2 interaction with β-catenin and KLF15 
This work aimed to characterize the role of cardiac specific Wnt/β-catenin 
components with a potential role on modulation of Wnt-context-dependent biological 
responses. Specifically, the basic leucine zipper and W2 domains containing protein 
(BZW) 2 was found to interact with Wnt components such as KLF15 and β-catenin. 
 
Under the following criteria BZW2 was selected for further analysis in the present 
study: I) reported high expression in adult rat heart82; II) biochemical characteristics 
(predicted DNA and protein domains) and III) conservation of the protein. Firstly, 
BZW2 interactions with β-catenin and KLF15 were validated by means of co-
immunoprecipitation (co-IP). Due to the suitability of the antibodies, the interaction of 
BZW2 and β-catenin was validated in murine heart tissue. BZW2 was 
immunoprecipitated using a monoclonal rabbit-anti-BZW2 antibody and β-catenin 
was detected by Western blot using a monoclonal mouse-anti-β-catenin antibody 
(Figure 11A). Detection of endogenous murine KLF15 was not possible due to 
unavailable good antibody (several commercial as well as extra produced antibodies 
were tested). To validate this interaction mouse FLAG-BZW2 and HA-KLF15 were 
overexpressed in HEK293 cells. FLAG-BZW2 was immunoprecipitated using 
monoclonal mouse-anti-FLAG antibody and HA-KLF15 was detected by Western blot 





Figure 11: Validation of BZW2 interaction with β-catenin and KLF15. 
Co-immunoprecipitation (co-IP) experiments validated BZW2 interactions with β-catenin and KLF15, 
visualized by Western blot analysis (IP = immunoprecipitation with specific antibody, IPIgG = 
immunoprecipitation with immunoglobulins as a negative control, L = lysate as a detection control, IB = 
immunoblot). A BZW2 was precipitated from adult murine heart tissue using monoclonal rabbit-anti-
BZW2 antibody. β-catenin was detected by Western blot using monoclonal mouse-anti-β-catenin 
antibody. B FLAG-BZW2 and HA-KLF15 were overexpressed in HEK293 cells. BZW2 was 
precipitated using monoclonal mouse-anti-FLAG antibody. KLF15 was detected by anti-HA-HRP 
antibody. 
 
Moreover, mass spectrometry analysis of co-immunoprecipitated BZW2 using mouse 
heart tissue was carried out at the Proteomic facility (UMG), in which β-catenin was 
identified (Figure 12). 
 
 
Figure 12: BZW2 interaction with β-catenin analyzed by mass spectrometry. 
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BZW2 protein was enriched from adult murine heart tissue by IP using monoclonal rabbit-anti-BZW2 
antibody (and rabbit-IgG as a control) and analyzed for interacting partners by mass spectrometry. 
Nanoflow liquid chromatography tandem mass spectrometry (LC-MS/MS) was performed at the 
Proteomics Facility of the UMG (Head: Prof. H. Urlaub / Dr. C. Lenz). The experiment was 
successfully repeated. A Enrichment of BZW2 was validated by BZW2 detection in the BZW2-IP 
fraction. B β-catenin was enriched in BZW2 enriched sample in contrast to IgG control. 
 
Next, to infer about the level of association of BZW2 with the identified proteins, cell 
localization of BZW2 was investigated by co-immunofluorescence and confocal 
analysis. FLAG-BZW2 was overexpressed with either β-catenin or HA-KLF15 in 
HEK293 cells. Cells were harvested after 48 h and fixed for staining using above 
described antibodies. Stained cells were analyzed by confocal microscopy. As 
expected, β-catenin was observed at the membrane, in the cytosol and nuclear cell 
compartments, and KLF15 exclusively in the nucleus (Figure 13). BZW2 was 
localized at the cytosolic and nuclear compartment. This analysis showed that BZW2 
is co-localized in common cellular compartments to β-catenin and KLF15, namely the 
cytosol, in which BZW2 was co-localized with β-catenin, and the nucleus, in which it 
was co-localized with both β-catenin and KLF15. 
 
 
Figure 13: Co-localization analysis of BZW2 with β-catenin and KLF15. 
BZW2 was found in cytosolic and nuclear compartments. FLAG-BZW2 and β-catenin as well as 
FLAG-BZW2 and HA-KLF15 were overexpressed in HEK293 cells. After two days of culture cells were 
fixed and stained with specific antibodies. β-catenin was detected by mouse-anti-β-catenin and anti-
Results 
55 
mouse-Alexa Fluor 488 (green) antibodies, KLF15 by mouse-anti-HA and anti-mouse-Alexa Fluor 488 
(green) antibodies, BZW2 by rabbit-anti-FLAG and anti-rabbit-Alexa Fluor 594 (red) antibodies. Cell 
nuclei were stained using DAPI (blue). Cells were analyzed by confocal microscopy using Z-stack. The 
pictures represent 3-dimensional Z-stack overlays generated from individual photos to ensure analysis 
of complete cell content including all sections through the cell. In the big box cells are represented 2-
dimensional in X- and Y-axes. In small green and red boxes cells are represented in the 3
rd
 dimension: 
Z-axis. Scale bar: 20 µm. 
 
To evaluate the biological relevance of this expression, murine heart sections were 
stained for BZW2 and Troponin T to visualize the endogenous localization of BZW2 
in this tissue (Figure 14). Cardiac Tropinin T was used to visualize adult 
cardiomyocytes. BZW2 was found to be strongly expressed in the nucleus but also 
found in the cytosol co-localizing with cardiac Tropinin T staining. 
 
 
Figure 14: BZW2 localization in cell compartments. 
BZW2 expression in heart tissue of adult NMRI mice was analyzed. BZW2 was found in the cytosol as 
well as in the nucleus. Confocal images were done from immunostained paraffin slides: BZW2 was 
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detected using rabbit-anti-BZW2 (Q91VK1) & anti-rabbit-Alexa Fluor 594 (red) antibodies. 
Cardiomyocytes were visualized by mouse-anti-troponin T (TropT) and anti-mouse-Alexa Fluor 488 
(green) antibodies, showing cytosolic staining and nuclei by DAPI (blue). Scale bar: 50 µm. 
4.1.2. BZW2 expression in mouse 
These results encouraged to further investigate the expression of BZW2 and its 
relevance for heart biology. The hypothesis was tested, that BZW2 is specific 
expressed in heart tissue. Tissue from different murine organs (heart, spleen, lung, 
liver, kidney, brain and skeletal muscle) was analyzed for BZW2 protein expression. 
The organs were collected and protein was extracted for Western blot analysis. 
BZW2 was observed highly expressed in the heart and skeletal muscle tissue in 
comparison to spleen, lung, liver, kidney or brain (Figure 15). GAPDH was used as 
housekeeping protein control for all analyzed organs and compared relative 
expression. We are aware of the difficulty of an ideal housekeeper expression in such 
an analysis due to its variability in different tissue. 
 
 
Figure 15: BZW2 protein expression in different murine organs. 
Western blot analysis showed high BZW2 expression in the heart and skeletal muscle tissue. Tissue 
lysate from heart, spleen, lung, liver, kidney, brain and skeletal muscle were analyzed for BZW2 
protein expression via Western blot (n=2/group). Same amount of total protein was loaded for every 
sample. BZW2 was detected using rabbit-anti-BZW2 antibody. GAPDH was detected using mouse-
anti-GAPDH antibody. 
 
This analysis indicated that BZW2 is indeed very high expressed in the heart but also 
in skeletal muscle, indicating a muscle specific factor under normal organ 
homeostasis. Moreover, high transcript expression of BZW2 was observed in heart 
and skeletal muscle human tissue in comparison to trachea, testis, spleen, prostate, 
ovary, mammary gland, lung, kidney, hippocampus, epidermis, cerebral cortex, 
cerebellum, aorta, adipose tissue (data not shown, collaboration partner personal 




Wnt transcriptional inhibiton mediated by the KLF15 complex was previously 
observed in CPC, which showed altered cell fate upon KLF15 loss of fuction. To 
evaluate the possibility that BZW2 forms part of this complex, BZW2 expression was 
first analyzed in different heart cell types. Cardiomyocytes, cardiac fibroblasts and 
cardiac progenitors were analyzed. Cardiomyocytes and cardiac fibroblasts were 
isolated from adult murine hearts via Langendorff perfusion method. For protein 
analysis fibroblasts were isolated using a collagenase-trypsin-digestion protocol. 
Cardiac progenitors were isolated with a protocol described by Zafiriou MP et al., 
2014.96 Cells were isolated using an antibody against the stem cell marker stem cells 
antigen (Sca) -1. The purity of the cells was controlled by flow cytometry analysis. 
Furthermore, qPCR analysis as used to further confirm the nature of the isolated 
population which indeed showed strong expression of Sca-1 and almost abscent 
expression of the cardiomyocytes marker cardiac troponin T (TropT), indicating the 
undifferenriated nature of this population.96 BZW2 was highly expressed in 
cardiomyocytes and cardiac progenitors compared to cardiac fibroblasts, detected via 
qPCR and Western blot. The tumor protein, translationally-controlled (TPT) 1 was 
used as a loading control.97-99 These observavtion indicate an important role of BZW2 
in CMs and CPC population. 
 
 
Figure 16: BZW2 expression in selected cardiac cell types. 
BZW2 expression was analyzed in cardiomyocytes (CMs), cardiac progenitor cells (CPCs) and cardiac 
fibroblasts (FBs). A Preliminary results indicated higher Bzw2 mRNA expression in cardiomyocytes 
and cardiac progenitors compared to fibroblasts (n=1/CMs; n=2/CPS; n=2/FBs). B In line, Western 
blot analysis demonstrated higher BZW2 protein expression in cardiomyocytes compared to 
fibroblasts (n=3/CMs; n=2/FBs). Due to the minor amount of isolated CPC, they were not used for 
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protein expression analysis. Tumor protein, translationally-controlled (TPT) 1 was detected using 
mouse-anti-TPT1 antibody for normalization. Cardiomyocytes isolation in this experiment was 
performed with help of Sebastian Pasch. 
 
The data showed above indicate a role of BZW2 in a mature and undifferentiated cell 
population. Since the expression of in embryonic development BZW2 was not 
characterized, we investigate its epxression in the developing heart. To do that, 
murine cardiac tissue at different developmental stages was collected: cardiac 
crescent (embryonic post coitum days E7.0-7.5), linear heart tube and looping heart 
(E8.5 & E9.5), embryonic hearts (E11.5, E13.5, E15.5 & E17.5), postnatal hearts 
(postnatal days P1, P3, P6, P8, P10 & P13) and adult heart (P60). For the cardiac 
crescent stage approximately 10 embryos per sample were used, for linear heart 
tube stage – 5-7 embryos per sample, for looping heart stage and at embryonic day 
E11.5 – 3-5 embryos. Postnatal and adult hearts were isolated without atria. Analysis 
by qPCR showed that Bzw2 mRNA was detected throughout heart development and 
in the postnatal heart. However, it could be observed that the expression was higher 
during early heart development at embryonic days 8.5 & 9.5 as well as in the adult 




Figure 17: Bzw2 mRNA expression during cardiac development in mice. 
Bzw2 mRNA expression was tested in cardiac tissue of MNRI mice at different developing stages 
(embryonic post coitum day = E; postnatal day = P, n=3/group). It was analyzed by qPCR and 
normalized to Tpt1 expression. Cardiac tissue was isolated from mice in different developing stages: 
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cardiac crescent (E7.0-7.5), linear heart tube and looping heart (E8.5 & E9.5), embryonic hearts 
(E11.5, E13.5, E15.5 & E17.5), postnatal hearts (P1, P3, P6, P8, P10 & P13) and adult heart (P60). At 
early stages cardiac tissue from several embryos was pooled together per sample: at E7.0-7.5 
approximately 10 embryos, at E8.5 – 5-7 embryos, at E9.5 & E11.5 – 3-5 embryos were pooled 
together to one sample. From stage P1 to adulthood, only ventricular tissue was analyzed. 
 
Furthermore, we were interested in the epxression pattern of BZW2 in whole embryo 
development. Therefore whole mount in situ hybridization was performed to 
investigate the mRNA Bzw2 expression pattern in the mouse embryo. A self-
designed sense (S) and antisense (AS) Bzw2 in situ probe was used for mRNA 
detection in embryos E9.5 and 10.5. Bzw2 was detected not only in the developing 
heart, but also highly expressed in somites, limbs and branchial arches in E9.5 and in 
somites, first and second branchial arches, midbrain/hindbrain, dorsal root ganglia as 
well as fore and hind limbs in E10.5, suggesting a role for BZW2 in development 
(representative picture in Figure 18). 
 
 
Figure 18: Bzw2 mRNA expression in the mouse embryo. 
Whole mount in situ hybridization with sense and antisense (AS) control Bzw2 in situ probe in embryos 
E9.5 and E10.5. A Arrows indicate the most prominent expression as indicated in the text. B: brain; P: 
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pharyngeal pouches; L: limbs; DRG: dorsal root ganglia; H: heart. B Expression in the heart is 
observed in the common ventricle (CV) and atria (CA). Experiment was performed by Eric Schoger 
with a modified protocol based on Zelarayán LC et al., 2007.
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4.1.3. BZW2 protein domains analysis 
Localization of BZW2 in different cell compartment was observed suggesting a 
dynamic transport of BZW2, which may dependent on pathway activation. Therefore, 
we next investigated the biochemical characteristics of the protein and tested the 
hypothesis that BZW2 contains a domain necessary for specific cell localization. Two 
truncated protein forms of BZW2 were designed. In one construct, the C terminus 
was deleted including nearly the complete W2 domain (Bzw2-∆C). In the second 
construct the N terminus was deleted including putative ZIP and bZIP domains 
(Bzw2-∆N) (Figure 19A). These constructs were validated via Western blot analysis 
from overexpressed HEK293 cells (Figure 19B). 
 
Figure 19: Validation of BZW2 truncated forms for domain analysis. 
A Schematic representation of all generated FLAG-tagged constructs. Full length BZW2 (BZW2-FL) 
includes putative ZIP, bZIP domains and W2 domain. In the C terminus truncated form (BZW2-∆C) 
nearly the complete W2 domain is deleted. In the N terminus truncated form (BZW2-∆N) putative ZIP 
and bZIP domains are deleted. 
 
The truncated Bzw2 constructs as well as the full length Bzw2 (Bzw2-FL) were 
separately transfected into HEK293 cells. Western blot analysis of BZW2 in 
fractionated cytosolic and nuclear fractions showed that BZW2-FL is located in both, 
cytosol and nucleus in overexpressed HEK293 cells. Deletion of C terminus including 
W2 domain leads to reduction of cytosolic localization. In contrast, deletion of N 
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terminus including putative ZIP and bZIP domains leads to reduction of nucleic 
localization (Figure 20). 
 
Figure 20: BZW2 protein domains analysis. 
A BZW2-FL, BZW2-∆C and BZW2-∆N were each overexpressed in HEK293 cells (n=3/group). Protein 
lysates were separated in cytosolic & nucleic fractions. BZW2 expression was detected via Western 
blot using mouse-anti-FLAG antibody. GAPDH (cytosol), lamin A/C (nucleus) and inactive form of 
caspase 3 (cytosol) were used as controls for separation. B BZW2 expression in cell compartments 
was normalized to the total BZW2 expression. Full length BZW2 (FL) is localized in both cell 
Results 
62 
compartments, predominantly in cytosol. Deletion of C terminus (∆C) leads to the reduction of the 
cytosolic localization, meanwhile deletion of N terminus (∆N) leads to the reduction of the nucleic 
localization. 
4.2. Investigation of BZW2 role in the Wnt/β-catenin signaling 
4.2.1. BZW2 expression upon upregulation of the Wnt/β-catenin 
signalling in vivo 
The above described experiments demonstrated an assoccitation of BZW2 
components of the Wnt/β-catnein cascede as well as strongly suggest an important 
role of BZW2 in signaling adult and developing heart cells. Next, we further 
investigated its role in the Wnt cascade. We found BZW2 upregulation in mice 
showing modulation of the Wnt/β-catenin cascade. Upregulation of the Wnt/β-catenin 
trasncriptional activity was previosly reported in Klf15 knock-out (KO) mouse heart as 
demosntrated by Tcf7l2 upregulation (Figure 4, Introduction, Page 10). Expression of 
Bzw2 was analyzed in heart, lung, liver and kidney from Klf15 knock-out (KO) mice in 
comparison to wild type C75BL/6N control mice. It was found that similar to the 
Tcf7l2 expression (Figure 4, Page 10) BZW2 expression was higher in Klf15 KO mice 








BZW2 expression was tested in the heart, lung, liver and kidney of the Klf15 knock-out (KO) mice 
compared to the wild type mice (WT). BZW2 was upregulated specifically in the heart, despite the 
global knock-out. Bzw2 mRNA expression was analyzed via qPCR and normalized to β-actin 
(n=6/group, Student’s t-test, **p<0.01). 
 
To corroborate the direct relation to the Wnt/β-catenin cascade activation, BZW2 
expression was analyzed in the heart of mice with an inducible α-Mhc specific β-
catenin stabilization (β-catenin∆ex3) resulting in Wnt/β-catenin transcriptional 
activation. Moreover the heart of mice with an inducible α-Mhc specific β-catenin (β-
catenin∆ex2-6) depletion resulting in reduced Wnt/β-catenin activation was analyzed. 
These double transgenic mice carry a tamoxifen inducible CRE recombinase driven 
by the α-Mhc promoter. β-catenin locus is flanked by loxP sites either at exons 3 
(including phosphorylation amino residues leading to β-catenin degradation), which 
results in a gain-of-function or at exons 2-6, resulting in a loss-of-function after 
recombination induced by Tamoxifen injection. In line with BZW2 expression in Klf15 
KO mice, BZW2 protein expression in the heart of β-catenin gain-of-function mice 
was also upregulated in comparison to the wild type mice (Figure 22), indicating 





Figure 22: BZW2 expression in cardiac specific β-catenin gain-of-function mice. 
BZW2 expression in the heart of cardiac specific β-catenin stabilized mice (β-cat
∆ex3
, described above) 
was analyzed by Western blot and normalized to GAPDH (n=6/group). BZW2 protein expression was 
upregulated in the heart of these mice compared to the wild type (WT). The graph represents analyzed 




Interestingly cardiac BZW2 protein expression under β-catenin downregulation was 
not changed compared to the wild type mice (Figure 23). Supporting a role as a 
negative feedback factor. 
 
 
Figure 23: BZW2 expression in cardiac specific β-catenin loss-of-function mice. 
BZW2 expression in the heart of cardiac specific β-catenin depleted mice (β-cat
∆ex2-6
, described 
above) was analyzed by Western blot and normalized to TPT1 (n=3). BZW2 protein expression was 
unchanged in the heart of these mice compared to the wild type (WT). The graph represents analyzed 
Western blot data. 
4.2.2. BZW2 role in the Wnt/β-catenin signalling as a downstream target 
gene 
High expression of BZW2 in mice under upregulation of the Wnt/β-catenin signaling 
opened another question, namely whether BZW2 itself is regulated by the Wnt/β-
catenin signaling. An in silico promoter analysis of the 5’-region of the ATG BZW2 
codon was performed using online available tools (http://alggen.lsi.upc.es). This 
identified three TCF/LEF putative consensus sequences 1745 bp upstream the Bzw2 
start codon. This fragment was cloned into pGL4.10 vector to drive luciferase gene 
expression for experimental testing (Figure 24A). Luciferase activity in this 
experimental set up represents Bzw2 transcriptional activity. Non-modified pGL4.10 
vector was used as a negative control (NC). Bzw2-promoter construct was co-
transfected with Tcf7l2. Renilla luciferase expressing plasmid was co-transfected for 
normalization. TCF7L2 overexpression significantly upregulated Bzw2 transcriptional 
activity (Figure 24B). These data suggest that Bzw2 transcription is regulated by 





Figure 24: Luciferase reporter assay indicating BZW2 role in the Wnt/β-catenin signaling as a 
target gene. 
A pGL4-Bzw2-prom plasmid includes luciferase gene driven by a sequences 1745 bp upstream the 
Bzw2 start codon including 3 TCF/LEF putative consensus sequences (a putative Bzw2 promoter). 
Unmodified pGL4.10 vector (not shown) was used as a negative control for unspecific binding to the 
vector in all experiments. B Significant increase of Bzw2 transcriptional activity by TCF7L2 in HEK293 
cells was detected by dual luciferase assay (n=3/group; Student’s t-test, ***p<0.001). Unmodified 
pGL4.10 vector was used as a negative control (NC). 
4.2.3. BZW2 role in the Wnt/β-catenin signalling as a co-regulator 
BZW2 was highly expressed in mice under upregulation but not under 
downregulation of the Wnt/β-catenin signaling. It opened a question whether BZW2 
was compensatory upregulated to inhibit the Wnt/β-catenin signaling in these mice. 
To test BZW2 putative regulatory role on the Wnt/β-catenin signaling the 
TOPflash/FOPflash reporter assay was used. TOPflash plasmid includes luciferase 
gene driven by TK-promoter with three TCF/LEF consensus sequences. FOPflash 
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plasmid includes 3 mutated TCF/LEF consensus sequences and was used as a 
negative control for unspecific binding to the plasmid (Figure 25A). Luciferase 
activity, detected by measurement of the luminescence produced from luciferin 
oxidation, represents indirect Wnt/β-catenin signaling transcriptional activity. 
TOPflash and FOPflash plasmids were single co-transfected into HEK293 cells with 
BZW2 expressing plasmid or with the empty vector as a negative control. Renilla 
luciferase expressing plasmid was co-transfected for normalization. By 
overexpression of BZW2 no significant changes of Wnt/β-catenin signaling activity 
were detected by luminescence changes (Figure 25B). 
 
 
Figure 25: BZW2 role in the Wnt/β-catenin signaling as a co-regulator. 
A TOPflash plasmid includes luciferase gene driven by TK-promoter with 3 TCF/LEF consensus 
sequences. FOPflash plasmid (not shown) includes 3 mutated TCF/LEF consensus sequences and 
was used as a negative control for unspecific binding to the plasmid in all experiments. B A tendency 
to inhibition of Wnt/β-catenin signaling activity by BZW2 in HEK293 cells was detected by 
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TOPflash/FOPflash reporter assay (n=4: triplicate of 4 independent experiments). FOP was used as a 
negative control. 
4.2.3.1. Influence of BZW2 on the Wnt/β-catenin signalling in vivo 
Since TOPflash/FOPflash reporter assay in HEK293 cells is a non-cardiac in vitro 
system, the putative BZW2 regulatory role on the Wnt/β-catenin signaling was further 
investigated in BZW2 transgenic mouse model (a Bzw2 knock-in (KI) mouse model 
with a conditional potential named as first allele Bzw2tm1a knock-out (KO), UC DAVIS 
KOMP Repository Knockout mouse project) (Figure 26). The initial unmodified allele 
is predicted to generate a null allele through splicing to a LacZ trapping element 
contained in the targeting cassette.101 They consist of a KI cassette including the 
Bzw2 locus at exon 4, flanked by loxP sites (for Cre recombination recognition). The 
insert upstream from the floxed exon 4 (including LacZ cesette following by loxP and 
neomycin resistance cassette) is flanked by flippase (Flp) recognition target sites 
(FRT). Consequently breading of these mice with constitutive Flp-recombinase mice 




Figure 26: Bzw2 KI transgenic mouse model with a conditional potential. 
The initial unmodified allele is predicted to generate a null allele through splicing to a LacZ trapping 
element contained in the targeting cassette (“first KO with conditional potential”). A knock-in (KI) 
cassette includes the Bzw2 locus at exon 4, flanked by loxP sites (for Cre recombination recognition). 
The insert upstream from the floxed exon 4 (including LacZ cesette following by loxP and neomycin 
resistance cassette) is flanked by flippase (Flp) recognition target sites (FRT). Consequently breading 
of these mice with constitutive Flp-recombinase mice would lead to a Cre-inducible KO mouse model. 
The following breading with tissue specific Cre-recombinase mice and induction of Cre-recombinase 
would lead to induced KO by exon 4 deletion with the following frame shift. 
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UC DAVIS KOMPRepository Knock out mouse project. 
 
Because of the time limit the Bzw2tm1a knock-out mice (in following named Bzw2 KI 
mice) were analyzed in this study. The insert upstream from exon 4 is approximately 
11 kb long and consists of β-galactosidase (LacZ) and neomycin resistance 
cassettes, each including own polyadenylation sites which should avoid BZW2 
translation. This is predicted to generate a null allele.101 To validate the model Bzw2 
KI mice (wild type, heterozygous and homozygous) were analyzed for BZW2 
expression. It was shown that already on the RNA level significant reduction of Bzw2 
expression took place in heterozygous (HE) and homozygous (HO) mice (Figure 
27A). BZW2 protein is reduced in the HE and is completely absent in the HO Bzw2 KI 
mice as observed via Western Blot by using a rabbit-anti-BZW2 antibody recognizing 
BZW2 protein region coding by exons 8-9 (Figure 27B). 
 
 
Figure 27: Validation of BZW2 expression in Bzw2 KI mice. 
Cardiac tissue of adult Bzw2 KI mice (heterozygous (HE) and homozygous (HO) mice) was analyzed 
for BZW2 expression compared to the wild type (WT) from the same mouse line. A Bzw2 mRNA 
normalized to Tbp expression is significantly reduced in heart tissue of HO mice (n=4/WT & n=5/HO; 
Student’s t-test, ***p<0.001). B BZW2 protein expression normalized to GAPDH is significantly 
decreased in HE mice and is absent in HO mice. The graph represents several Western blot analyses 
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(n=9/WT & n=3/HE & n=7/HO, Student’s t-test, *p<0.05), some of them performed with the help of Eric 
Schoger. 
 
BZW2 protein expression in Bzw2 KI was validated using rabbit-anti-BZW2 antibody 
binding the protein region coding by exons 8-9, which seems to be absent upon 
translation of the Bzw2 KI locus. However, the use of a rabbit-anti-BZW2 antibody 
(Q91VK1, designed and produced by Thermo scientific) binding the protein region 
coding by exon 3 (upstream of the insert) was able to show protein expression by 
immunohistochemistry analyses. Validation of the truncated BZW2 protein by 
Western blot was not possible, due to the antibody did not work for this analysis. 
Paraffin sections of adult Bzw2 KI mice (WT and HO) were used for 
immunofluorescence analysis. Interestingly, expression of BZW2 was detected in HO 
Bzw2 KO mice (accuracy of the antibody was tested by several in vitro testing for 
cross reaction with BZW1, data not shown). This data suggest a truncated protein is 
generated in Bzw2 KI mice, whose cytosol/nucleus distribution remains to be 
investigated (Figure 28). 
 
Figure 28: BZW2 truncated protein is expressed in the heart of homozygous Bzw2 KI mice. 
Expression of truncated BZW2 protein in heart tissue of adult HO Bzw2 KI mice was analyzed 
compared to WT and antibody control. BZW2 was detected using rabbit-anti-BZW2 binding in the 
region coding by exon 3 (Q91VK1, designed and produced by Thermo scientific) & anti-rabbit-Alexa 
Fluor 594 (red) antibodies. Nuclei staining was done by DAPI (blue). BZW2 truncated form was found 
in the nucleus. Confocal images were done from immunostained paraffin slides. Scale bar: 20 µm. 
 
To investigate the effect of BZW2 on the Wnt/β-catenin cascade, firstly β-catenin 
immunostaining was performed in paraffin section of adult Bzw2 KI mouse hearts. 
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This analysis showed an increased expression of β-catenin in HO Bzw2 KI mice 
compared to the wild type, which is apparently located at the membrane, although it 
is important to note that immunofluorescence detection of β-catenin in the nucleus in 
paraffin sections has been challenging. 
 
Figure 29: β-catenin is upregulated in the heart of homozygous Bzw2 KI mice. 
Heart tissue of adult HO Bzw2 KI mice was analyzed for β-catenin expression compared to WT and 
antibody control. β-catenin was detected using mouse-anti-β-catenin & anti-mouse-Alexa Fluor 488 
(green) antibodies. BZW2 was detected by rabbit-anti-BZW2 (Q91VK1, Thermo scientific) & anti-
rabbit-Alexa Fluor 594 (red) antibodies. β-catenin was found upregulated and accumulated on the 
plasma membrane in heart tissue of Bzw2 KI mice. Confocal images were done from immunostained 
paraffin slides: Nuclei staining was done by DAPI (blue). Scale bar: 20 µm. 
 
For further investigation RNA and protein from Bzw2 KI mice hearts were analyzed. 
In line with the immunofluorescence data, β-catenin was found to be significantly 
increased in the HO Bzw2 KI mice (Figure 30A and B). Interestingly, β-catenin 
expression was not changed in the HE mice, indicating that the complete absence of 
the protein (or part of it) is necessary for β-catenin dysregulation. To test if this 
regulatory effect is cardiac specific, RNA from different organs (heart, skeletal 
muscle, brain, spleen, liver, kidney and lung) of Bzw2 KI mice (HO mice compared to 
the wild type) was analyzed for β-catenin expression. β-catenin was significantly 




Figure 30: β-catenin expression analyses in Bzw2 KI mice. 
Cardiac tissue of adult Bzw2 KI mice (heterozygous (HE) and homozygous (HO) mice) was analyzed 
for β-catenin expression compared to the wild type (WT) from the same mouse line. A β-catenin 
mRNA normalized to Tbp expression is significantly increased in heart tissue of HO mice (n=4/WT & 
n=5/HO; Student’s t-test, **p<0.01). B β-catenin protein expression normalized to GAPDH is 
unchanged in HE mice but is significantly increased in HO mice. The graph represents several 
Western blot analyses (n=9/WT & n=3/HE & n=7/HO, Student’s t-test, **p<0.01), performed with the 
help of Eric Schoger. C β-catenin mRNA normalized to Tbp is significantly increased exclusively in 
heart tissue of HO mice compared to skeletal muscle, brain, spleen, liver, kidney and lung tissue 
(n=4/WT heart & HO kidney; n=3/HO lung; n=5/other groups; Student’s t-test, ***p<0.001). 
 
These data together suggest that BZW2 deletion leads to cardiac specific 
upregulation of β-catenin expression, the key protein of the Wnt/β-catenin signaling. 
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4.3. Investigation of BZW2 role in the normal heart homeostasis 
Next, the BZW2 role in the adult heart homeostasis in vivo was investigated. To test 
whether BZW2 reduction has an effect in heart function, HE Bzw2 KI mice (described 
in 4.2.3.1., Page 67) were analyzed via echocardiography, a standard method based 
on a sonogram of the heart. Mice were anesthetized by 2% isoflurane inhalation and 
ventricular measurements were done with a Visual Sonics Vevo 2100 Imaging 
System equipped with a 45 MHz MS-550D MicroScan transducer at the SFB 1002 
echocardiography facility. First the mice were analyzed at baseline in the absence of 
any stimulus. Moreover, two groups were subjected to TAC, 12 weeks old HE mice 
and 8 weeks old HO mice with the respective age-matched-wild type mice from the 
same line used as a control. 
 
Analysis of the geometry of the heart, as indicative of remodeling, showed that 
anterior wall thickness of the left ventricle in diastole (AWTh-d) was significantly 
increased in the 12 weeks old HE mice while the 8 weeks HO mice showed a non-
significant increase (Figure 31A). Interestingly, this increase was primarily observed 
in female mice (Figure 31B). Moreover, anterior wall thickness in systole (AWTh-s) 
was significantly increased in females of the 12 weeks old HE and in the 8 weeks old 
HO (Figure 31C). 12 weeks old HE females showed an increased cardiac mass as 
indicated by increased heart weight relative to body weight (HW/BW), but no increase 
of this ratio was observed in 8 weeks old HO females (Figure 31D). Interestingly, the 
HO females seemed to be heavier than WT females, which can explain why despite 
a significant increased heart weight they had no changes in the heart weight relative 
to body weight (Figure 31E). Nevertheless, no significant functional changes were 
observed neither in 12 weeks HE nor in 8 weeks HO mice, as showed by fraction 









Figure 31: Echocardiography analysis of Bzw2 KI mice. 
Cardiac functional phenotype of Bzw2 KI mice were analyzed by echocardiography with a 45 MHz 
MS-550D MicroScan transducer. Heterozygous (HE) mice were analyzed in the age of approximately 
12 weeks and homozygous (HO) mice in the age of approximately 8 weeks, compared to the wild type 
(WT). Mice number: n=27 HE (27 WT); n=21 HO (21 WT); n=14 HE females (12 WT); n=11 HO 
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females (10 WT); Student’s t-test, *p<0.05, ***p<0.001. A Anterior wall thickness of the left ventricle in 
diastole (AWTh-d). B AWTh-d, depend on mouse gender. C Anterior wall thickness of the left ventricle 
in systole (AWTh-s) of HO mice and HE females. D Heart weight relative to body weight (HW/BW) in 
female mice. E Heart weight (HW) and body weight (BW) in female mice. F Left ventricle internal 
diameter in diastole (LVID-d) in HO females. G Fraction area shortening (FAS, n=13 HE females (11 
WT)) and ejection fraction (EF) in female mice. 
 
To test if cardiac functional changes develop with aging, 47 weeks old HE mice were 
analyzed. Indeed, Bzw2 KI mice showed a significant decrease of the cardiac 
function demonstrated by fraction area shortening (FAS) and ejection fraction (EF) 
(Figure 32A). This was accompanied with a significant decrease in anterior wall 
thickness in systole (AWTh-s) and increased internal left ventricle area in systole 






Figure 32: Echocardiography analysis in aged Bzw2 KI mice. 
Cardiac characteristics of heterozygous Bzw2 KI mice (HE) in the age of approximately 47 weeks 
were analyzed by echocardiography, compared to the wild type (WT). Mice number: n=10 HE (5-6 
WT); Student’s t-test, *p<0.05. A Fraction area shortening (FAS) and ejection fraction (EF). B Anterior 
wall thickness of the left ventricle in systole (AWTh-s) and interior left ventricle area in systole (Area-s). 
 
All together these data indicate that BZW2 loss and even a reduction results in 
hypertrophic remodeling with a concomitant development of decreased cardiac 
function in mice. 
4.4. Investigation of BZW2 role in stress-induced cardiac remodelling 
4.4.1. BZW2 expression in cardiac disease 
Next, the role of BZW2 expression in cardiac diseases was analyzed. BZW2 was 
found to be upregulated in the heart tissue of mice with angiotensin (Ang) II -induced 
Results 
77 
cardiac hypertrophy (Figure 33A) as well as in human hearts with dilated (DCM) and 
ischemic (ICM) cardiomyopathies (Figure 33B). This suggest that BZW2 is part of a 
developmental activated gene upon remodeling. 
 
Figure 33: BZW2 expression in cardiac disease. 
Western blot analyses showed that cardiac BZW2 expression normalized to TPT1 was upregulated in 
(A) angiotensin II (Ang II) treated mice (n=3) in comparison to control animals (CTRL; n=4) (protein 
lysates kindly provided by A El-Armouche) as well as in (B) patients with dilated (DCM) (n=11) and 
ischemic (ICM) (n=10) cardiomyopathy in comparison to non-failing human hearts (NF) (n=3) (tissue 
samples kindly provided by K Toischer / G Hasenfuss). Student’s t-test, *p<0.05. 
4.4.2. Transverse aortic constriction (TAC) in Bzw2 KI mice 
In the TAC model the constriction of the aorta is done in the area of the aortic arch 
between the brachiocephalic artery and the left common carotid artery (Methods, 
Figure 9, Page 49), leading to a pressure overload in the heart in systole. TAC 
initially leads to compensated hypertrophy of the heart. Over time the response to the 
chronic hemodynamic overload becomes maladaptive, resulting in cardiac dilatation 
and heart failure.102 This is an excellent well established model to study the process 




HE Bzw2 KI mice were investigated compared to wild type age-matched mice. Sham 
operated mice were used as control for TAC. Heart geometry, size and function were 
analyzed by echocardiography 1-2 weeks before TAC operation (Pre), 2 and 4 weeks 
after TAC operation (Post 2 and Post 4) as well as by RNA analysis (5 weeks after 
TAC). As expected, TAC-induced cardiac hypertrophy and heart failure was 
developed as shown by increased anterior wall thickness and cardiac mass (Figure 
34A) as well as decreased cardiac function demonstrated by fraction shortening and 
ejection fraction (Figure 34B) in wild type mice. Similar results were observed in HE 
Bzw2 KI mice, with the difference that 4 weeks after TAC they showed less of AWTh 
compared to the wild type. This was oberved in HE when compared to WT at the 
same time point but also when compared to HE Bzw2 KI at 2 weeks (Figure 34A). 
These data suggest a thinning of the wall maybe due to higher wall stress compared 
to WT mice. As shown in Figure 34B, cardiac function starts to decrease around 4 
weeks post-TAC although this change is not significant. Due to the low mice survival 





Figure 34: Echocardiography analysis in TAC operated Bzw2 KI mice. 
Cardiac characteristics of heterozygous Bzw2 KI mice (HE) were analyzed by echocardiography, 
compared to the wild type (WT), before (Pre), 2 weeks after (Post2) and 4 weeks after (Post4) TAC 
operation. Sham operated mice were used as control. Mice number: n=8-10 in each Sham group; 
n=18/Pre, 12/Post2 & 6/Post4 in TAC operated WT group; n=16/Pre, 14/Post2 & 11/Post4 in TAC 
operated HE group; Student’s t-test, *p<0.05. A Heart weight relative to body weight (HW/BW), 
anterior wall thickness of the left ventricle in systole (AWTh-s) and diastole (AWTh-d). B Fraction area 
shortening (FAS) and ejection fraction (EF). 
 
Heart tissue was collected 5 weeks after TAC and used for gene expression analysis 
by qPCR. Atrial natriuretic peptide (ANP, encoded by Nppa) and brain natriuretic 
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peptide (BNP, encoded by Nppb) are hormones of cardiac origin, which expression 
increases in accordance with the severity of the heart failure.103 Both hormones were 




Figure 35: Hypertrophy marker in TAC operated Bzw2 KI mice. 
Nppa and Nppb mRNA expression was analyzed in heterozygous Bzw2 KI mice (HE) compared to the 
wild type (WT) by qPCR, Sham operated mice were used as control. Expression was normalized to 
Tbp. Mice number: n=4/Sham-WT; n=3/Sham-HE; n=5/TAC-WT; n=4/TAC-HE. 
 
All data together suggest that BZW2 is important to maintain normal adult heart 
homeostasis and for the compensatory response to cardiac stress. 
4.5. Investigation of BZW2 role in in vitro cardiogenesis 
4.5.1. Generation of BZW2 gain-of-function in murine embryonic stem 
cells (ESCs) 
We further investigate the specific role of BZW2 cardiac cell formation using and in 
vitor cardiogenesis model. To test the suitability of an in vitro model of cardiogenesis 
for studying the effect of BZW2 overexpression, BZW2 expression was investigated 
in murine embryonic stem cells (mESCs) in the process of cardiac differentiation. 
Similar to the expression observed in vivo, Bzw2 was highly expressed at day 0 of 
the differentiation and decreased continuously to day 16 (Figure 36). Important to 
note is that cardiomyocytes derived from stem cells are not fully mature showing 
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fetal/neonatal characteristics104, which could explain the maintained lower level of 
Bzw2 expression in later stages in contrast to the increase observed from early 
neonatal to adult heart in mouse in vivo. 
 
 
Figure 36: Analysis of Bzw2 expression in murine ESCs during differentiation to 
cardiomyocytes. 
Bzw2 mRNA expression normalized to Tpt1 decreases during spontaneous cardiomyocytes 
differentiation from murine ESCs. Cells underwent several transitions: day (d) 0 – pluripotent cells; d4 
– mesodermal / cardiac mesodermal cells; d9 – cardiac progenitors / immature cardiomyocytes; d16 – 
immature cardiomyocytes. 
 
mESC lines overexpressing BZW2 were generated for cardiomyocytes differentiation 
experiment. A plasmid including murine Flag-Bzw2 transcript under CMV-promoter 
as well as puromycin resistance gene under SV40-promoter was transfected into 
ESCs expressing neomycin resistance gene as well as green fluorescence protein 
(GFP) gene under cardiac specific α-Mhc-promoter for later selection and 
visualization of cardiomyocytes during differentiation. 1.5×106 cells were 
electroporated with 2 µg linearized DNA and cultured for 2 days. After 12 days of 
puromycin selection 96 clones were picked, expended and snap frozen. 48 of them 
were collected for BZW2 expression analysis. Clones containing CMV-Flag-Bzw2 
construct were identified via PCR (Figure 37) using specific primers detecting the 
insert DNA, which bind forward in CMV promotor and reverse exactly between exons 





Figure 37: Validation of CMV-Flag-Bzw2 construct integration in genomic DNA of ESCs. 
Integration of CMV-Flag-Bzw2 construct into DNA of ESCs was tested via PCR using specific primers 
and agarose gel electrophoresis. Pl = plasmid as a positive control, WT = untransfected ESCs as a 
negative control. 
 
The CMV-Flag-Bzw2 construct expression in selected clones was analyzed by 
mRNA and protein analyses (Figure 38). Two clones (#15 and #34) were chosen 
based on expression ratio of mRNA and protein analyses of the total BZW2 
expression. BZW2 transgene expression as well as endogenous expression was 





Figure 38: BZW2 expression analyses of ESC clones. 
The transgene expression (A, B) as well as the total BZW2 (transgene and endogenous) expression 
(C, D) were tested via qPCR (A, C) and Western blot (B, D). The mean of the BZW2 expression 
normalized to GAPDH of the untransfected ESCs (WT) as a negative control (n=3) was set to 1 and 
was used for normalization of clones. Clones #15 and #34 were chosen for following differentiation 
experiments. 
4.5.2. BZW2 role in the ESCs differentiation to cardiomyocytes 
The selecteed BZW2 overexpressing clones ESC-FLAG-BZW2#15 and #34 as well 
as untransfected ESCs as a negative control were used for differentiation to 
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cardiomyocytes via embryoid body formation method as previously described.26 The 
strongest BZW2 gain-of-function was detected in clone #15 (Figure 39A). Briefly, 
cells were collected at day 0 (pluripotent cells) in hanging drops in differentiation 
medium for embryoid bodies (EBs) formation. At day 3 (predominantly mesoderm) 
EBs were collected in medium and at day 5 (mesoderm / cardiac mesoderm) plated 
for further differentiation. From day 11 on (cardiac progenitors differentiation towards 
cardiomyocytes) cardiomyocytes were selected by neomycin (Figure 39B). To 
analyze the BZW2 role during differentiation samples from days 0, 4, 9 (cardiac 
progenitors / differentiating cardiomyocytes) and 16 (cardiomyocytes) were collected 
for expression analysis. Moreover EBs were measured at days 3 and 5 (Figure 39C) 




Figure 39: Differentiation of BZW2 gain-of-function ESCs to cardiomyocytes. 
A The highest total BZW2 expression normalized to GAPDH was observed in clone #15 from chosen 
ESC lines showing via Western blot. WT = untransfected cells. B The workflow of the differentiation 
experiments to cardiomyocytes (described above) shows cell type changes during differentiation. 
Modified from Renger A et al., 2013.
26
 C To detect EBs size as an evidence for differentiation capacity 
their perpendicular diameters (D) were summarized and divided by two. 
 
The undifferentiated (d0) BZW2 overexpressing clones did not show any 
morphological apparent phenotype. During differentiation experiments towards 
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cardiomyocytes EBs size was significantly decreased at day 3 as well as at day 5 
inversely proportional to BZW2 expression (Figure 40). 
 
 
Figure 40: BZW2 role in early cardiac differentiation. 
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A BZW2 overexpressing ESCs (clones #15 & #34 versus control (WT)) were observed during 
differentiation. Whereas at day 0 BZW2 overexpressing clones did not show any morphological 
apparent phenotype, at days 3 and 5 formed embryoid bodies (EBs) were decreased in size compared 
to the WT (scale bar 200 µm). B Measured diameters of EBs at days 3 and 5 of differentiation are 
demonstrated in a graph (differentiation experiment number n=4/day3 & n=3/day5; Student’s t-test, 
*p<0.05). 
 
At the 16th day of the differentiation control cells have formed extensive beating areas 
strongly expressing GFP. In contrast, first beating areas and very weak GFP signal 
started to appear in clone #34 at this time point. Neither beating areas nor GFP 
fluorescence were detected in clone #15 indicating inhibition of cardiomyocytes 
differentiation according to high BZW2 overexpression (Figure 41). 
 
 
Figure 41: Differentiation efficiency of BZW2 overexpressing ESCs. 
BZW2 overexpressing ESCs (clones #15 & #34 versus control (WT)) were observed at differentiation 
day 16. Whereas control cells developed wide beating areas strongly expressing GFP, first beating 
areas and very weak GFP signal started to appear in clone #34. Neither beating areas nor GFP 
fluorescence were detected in clone #15 (scale bar 1000 µm). 
 
To uncover the cause of reduced EBs formation under BZW2 upregulation, 
expression analyses were performed. Octamer binding transcription factor (Oct) 4 
expression in undifferentiated cells (d0) indicated that BZW2 overexpressing clones 
exhibited higher pluripotency potential compared to control at the starting point of the 
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differentiation (Figure 42A). Proliferation capability in BZW2 overexpressing clones at 
day 0 did not differ from the control, as indicated by cyclin-D1 (Ccnd1) expression 
(Figure 42B). Interestingly, the cardiac mesodermal marker mesoderm posterior 
(Mesp) 1 was dramatically downregulated in BZW2 gain-of-function cells at the 
differentiation day 4 compared to the control (Figure 42C). This indicates cardiac 
mesodermal formation abrogation by BZW2 overexpression. Next, it was tested 
whether this inhibition takes place already at mesoderm induction. Indeed the pan-
mesodermal marker brachyury (Bry) was significantly downregulated. This 
downregulation occurred already at d0 (Figure 42D). To distinguish whether the 
detrimental effect in cell specification was specific for mesoderm or a general effect, 
marker expression of other germ layers, endoderm and ectoderm, were tested. 
Interestingly, the endoderm marker SRY-related HNG-box (Sox) 17 was reduced in 
clone #15 at d0 and increased at d4 (Figure 42E), whereas the late ectoderm marker 
bone morphogenetic protein (Bmp) 4 was upregulated in both gain-of-function clones 
at d0 and in clone #15 at d4 (Figure 42F). These data indicate that EBs size 
reduction in BZW2-clones was caused by the inhibition of the mesoderm formation by 






Figure 42: Expressing analysis of BZW2 overexpressing ESCs at differentiation days 0 and 4. 
BZW2 overexpressing ESCs (clones #15 & #34 versus control (WT)) were analyzed at differentiation 
days 0 and 4 for mRNA expression via qPCR to look into reduced EBs formation in transgenic clones 
(normalized to Tpt1; differentiation experiment number n=3/group; Student’s t-test, *p<0.05, **p<0.01, 
***p<0.001). A Expression of Oct4 as a pluripotency marker. B Ccnd1 as a proliferation marker. C 
Mesp1 as a cardiac mesodermal marker. D Bry as a mesodermal marker. E Sox17 as an endodermal 




Next, the effect on the Wnt/β-catenin signaling was tested. β-catenin as well as its 
target gene Tcf7l2 were upregulated at d4 (Figure 43), which can be due to the 
increased endoderm population. 
 
 
Figure 43: The Wnt/β-catenin cascade in BZW2 overexpressing ESCs. 
BZW2 overexpressing ESCs (clones #15 & #34 versus control (WT)) were analyzed at differentiation 
days 0 and 4 for Wnt/β-catenin signaling activity by mRNA expression analysis (normalized to Tpt1; 
differentiation experiment number n=3/group; Student’s t-test, *p<0.05, **p<0.01). β-catenin was 
significantly increased in clone #15 at day 4. Tcf7l2 expression was significantly increased in both 






Wnt signaling is crucial for development in all species and especially in cardiogenesis 
it has a distinct time specific role.36 At the same time it is one of the pivotal signaling 
pathways regulating pathological and regenerative processes in many systems.69 
Importantly, several studies have suggested the important role of the Wnt/β-catenin 
signaling pathway in cardiovascular diseases. Components of the Wnt pathway at 
every level of regulation (such as membrane FZ, Wnt proteins, DVL-1, cytosolic β-
catenin, Axin2) were found to be upregulated in hypertrophic and post-ischemic 
hearts in mice and rats as well in human hearts in end-stage heart failure70-74, 105-107, 
while in the normal adult heart homeostasis the transcriptional activity of the pathway 
seems to be very low68. Studies in transgenic mouse lines showed that 
downregulation of the Wnt/β-catenin signaling under pathological cardiac conditions 
lead to a significant improvement in cardiac function. Mice with cardiac specific β-
catenin deletion indicated impaired hypertrophy development in TAC model80 and 
improved cardiac function after myocardial infarction77. Thus, the modulation of the 
Wnt/β-catenin signaling is an attractive approach to maintain cardiac function under 
pathological conditions. However, the molecular mechanisms determining context-
specific regulation and responses of the ubiquitous Wnt/β-catenin pathway in adult 
heart cells remain largely unknown. Previous work of the group described a binding 
of the factor KLF15 to β-catenin and TCF7L2 in the cell nucleus as well as an 
inhibition of the Wnt/β-catenin transcriptional signaling by KLF15.78 This inhibition 
was found cardiac specific (Noack C et al., unpublished) as increased activation of 
the Wnt/TCF transcription (due to the loss of inhibition) was observed in heart tissue 
in a mouse model with a global KLF15 functional deletion78. Since KLF15 is not 
predominantly expressed in the heart, the hypothesis was tested that cardiac specific 
co-factors were potentially required for this regulation. Screening a human cardiac 
library, BZW2 was identified as an interaction partner of β-catenin and KLF15 by 
yeast-2-hybrid screen (Renger A et al., unpublished). BZW2 was previously 
described to be highly expressed in the rat heart.82 The present study tested the 
hypothesis that BZW2 is a cardiac specific component of the Wnt/β-catenin signaling 
and plays a role in cardiogenesis and adult heart homeostasis. 
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5.1. BZW2 is associated with the Wnt/β-catenin signalling components 
In this study, an endogenous interaction between BZW2 and β-catenin was validated 
using murine heart tissue by co-immunoprecipitation and mass spectrometry 
analyses. Moreover, an interaction with KLF15 could be validated by co-
immunoprecipitation by overexpressing experiments in HEK293 cells. These data 
indicate that BZW2 is able to bind both β-catenin and KLF15, both described 
components of the Wnt/β-catenin pathways. BZW2 could be detected in both cell 
compartments, nucleus and cytosol. However, its abundance varied in different cell 
types. Overexpressed BZW2 protein was predominantly found in cytosol in HEK293 
cells. Analyses of endogenous expression in heart tissue revealed a predominant 
BZW2 localization in the nucleus in comparison to cytosol. Previous reports showed 
the localization of BZW2 in cytosol of PC12 cells in overexpression assay.108 These 
indicate that BZW2 cell localization depends on the cell type and that can be 
associated to cell specific function of the protein. A predominantly cytosolic BZW2 
localization is observed upon overexpression in HEK293 and PC12 cells with an 
embryonic origin and a nuclear localization is observed in adult heart tissue reflecting 
different functions of BZW2 in embryonic and adult cells. Moreover, cell specific post-
transcriptional modifications of BZW2 may be required for its nuclear localization. In 
addition, overexpressed BZW2 (HEK293, PC12) could lack a complete endogenous 
activation for nuclear localization. Importance of endogenous activation for cell 
localization was demonstrated in a study using β-catenin stabilization in Kep1 cells 
(murine mammary epithelial cell line). In this system, upstream induced Wnt signaling 
led to upregulation of β-catenin, its recruitment to the plasma membrane and 
activation of target gene transcriptional activity, in contrast, overexpressed β-catenin 
was distributed in the cytosol and led to very low activation of target gene 
transcription.109 
Since localization of KLF15 and β-catenin coincides in the nuclear compartment, the 
findings in this study suggest that BZW2 is a potential simultaneous nuclear partner 
of β-catenin and KLF15. An approach was taken, in which only the nuclear fraction of 
heart lysates was submitted to mass spectrometry, however, the stringent protocol 
needed for the nuclear fraction interfered with the detection of associated proteins by 
mass spectrometry in this cell fraction. 
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5.2. Different BZW2 protein domains are responsible for a dynamic cellular 
localization 
BZW2 possesses structural characteristics typical for transcription factors (acting in 
the nucleus) – putative ZIP and bZIP domains, as well as for translation initiation 
factors (acting in the cytosol) – W2 domain. In this study, the analysis of two 
truncated BZW2 forms demonstrated that the loss of the BZW2 N-terminus leads to 
significant reduced nuclear and increased cytosolic localizations in HEK293 cells. 
This may be explained by the fact that BZW2 N-terminus includes putative ZIP and 
bZIP domains, characteristic for DNA binding and that this fragment contains either a 
NLS or that the DNA binding domains are sequestering the protein attached to the 
chromatin and therefore leading to a shift of localization in the nucleus. Moreover, the 
BZW2 C-terminus includes a W2 domain, characteristic for protein-protein binding. 
The loss of the BZW2 C-terminus, although not significant, shifted the protein to a 
less cytosolic and more nuclear localization indicating that the W2 domain may be 
relevant for the cytosolic function and localization. A translational function of the W2 
domain in BZW2 was already proposed based on W2 function in eukaryotic 
translation initiation factors86, 110 in overexpressed HeLa cells. However, a role in 
translation remains to be confirmed in other cells and was out of the scope of this 
study. 
5.3. Bzw2 is highly expressed during cardiogenesis and in the adult heart. 
In line with reported mRNA expression data showing high expression of BZW2 in 
heart tissue82, BZW2 protein was found to be highly expressed in the adult heart and 
skeletal muscle tissue compared to other murine organs (brain, spleen, liver, kidney 
and lung) in this study. This finding is further support by the data shared from our 
collaboration partner (Personal communication, David Zhang, Pharmaceutical 
Division, Roche AG), showing the same finding in human tissue and strongly 
suggesting a conserved role for BZW2 in adult muscle tissue. 
 
Expression analysis helps to infer the biological role of a gene product, therefore in 
this study a comprehensive expression analysis was performed for Bzw2 since no 
data were available. In the whole embryo before midgestation, Bzw2 was expressed 
strongly in somites, limbs, first and second branchial arches, midbrain/hindbrain, and 
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dorsal root ganglia beside the heart. This pattern is similar to the α-skeletal actin 
gene expression, indicating a potential similar role of both genes during 
embryogenesis.111 Furthermore, expression of Bzw2 specifically during murine 
cardiac development demonstrated a higher mRNA expression in early cardiac 
development (post coitum days 8.5-9.5), where differentiation and establishment of 
the different heart fields takes place112, as well as in the complete matured heart. 
Interestingly, Bzw2 expression was lower in late-embryonic (started at post coitum 
day 11.5) and in neonatal/early-postnatal (till last analyzed postnatal day 13) heart 
tissue, where maturation of the heart takes place112, 113. In line with this finding, Bzw2 
was highly expressed in undifferentiated adult cells as well as in cardiomyocytes of 
adult mouse heart (compared to cardiac fibroblasts). These data suggest a role of 
BZW2 in undifferentiated cells of the developing and adult heart, as well as in mature 
cardiomyocytes. However, the lack of BZW2 in HO mice, did not dramatically affect 
embryonic development (data not shown), but results in an incomplete penetrance of 
retarded development as analyzed in the Bachelor Thesis of Eric Schoger.114 These 
data indicate a possible compensatory role of proteins with similar structure. Further 
supporting this observation, high Bzw2 expression was detected in murine embryonic 
stem cells (ESCs) with subsequent decrease during spontaneous cardiac 
differentiation towards cardiomyocytes, which lead to the formation of neonatal-like 
cardiomyocytes rather than mature cells in vitro104. Together these data indicate a 
decrease of BZW2 expression in the process of the cardiomyocytes maturation 
whereas expression in terminally differentiated mature cardiomyocytes increases 
again. This suggests different functions in the process of final differentiation and in 
maintaining normal heart homoeostasis. Interestingly, high expression of BZW2 
coincides with low Wnt activation in the process of cardiac differentiation but also in 
the adult normal heart. This suggests further a possible role of BZW2 in contributing 
to low activity of the Wnt cascade. 
5.4. BZW2 is a cardiac specific factor of the Wnt/β-catenin signalling 
BZW2 role on the Wnt/β-catenin signaling was investigated. Overexpression of 
BZW2 demonstrated mild inhibition of the Wnt-transcriptional-dependent luciferase 
activity, which was even less prominent upon increased TCF/LEF transcriptional 
activation by overexpression of β-catenin (data not shown). We hypothesize that 
BZW2 may act as a scaffold protein mediating the cardiac specific effect of KLF15-
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meditated Wnt cascade inhibition. BZW2 may be necessary for a complex formation 
without a significant effect on the transcription per se. Since HEK293 cells show a 
low mRNA expression of Klf15 as measured by relative qPCR quantification (Noack 
C et al., unpublished), it may explain the non-significant effect on the Wnt/β-catenin 
signaling by overexpressed BZW2 in this system. Other method for future analysis 
might be, to test if a KLF15 overexpression combined with a complete endogenous 
BZW2 deletion would still induce inhibitory effect on the Wnt/β-catenin signaling in 
HEK293 cells. 
 
To investigate the effect of different deletion doses of BZW2 on Wnt/β-catenin 
signaling as well as the effect on tissue development and homeostasis a Bzw2 
knock-in (KI) model with a conditional potential, named as first allele Bzw2tm1a knock-
out (KO) was used. The initial unmodified allele is predicted to generate a null allele 
downstream of exon 3 through splicing to a LacZ trapping element contained in the 
targeting cassette.101 The model was validated by analyzing mRNA and protein 
expression. Using an antibody against the C-terminal W2 domain of BZW2 no protein 
was detected by Western blot analysis. Interestingly, a second antibody against N-
terminal protein region coding by exon 3 showed detection of BZW2 in the KI 
homozygous hearts. This indicates expression of a short BZW2 N-terminal fragment 
including ZIP domain coding by exon 3 in these mice. This would fit with a model, in 
which the protein is translated to a point in which the frame is altered between exon 3 
and exon 4, resulting in a truncated protein product. Interestingly, under BZW2 
deletion in both alleles β-catenin protein expression was found significantly 
upregulated in the adult cardiac tissue. β-catenin phosphorylation modifications 
leading to stabilization of the protein remains to be analyzed but analysis of β-catenin 
mRNA expression revealed that BZW2 deletion leads to de novo transcriptional 
synthesis of β-catenin. Furthermore, BZW2 dependent de novo synthesis of β-
catenin was analyzed for its cardiac specificity in adult mice. Indeed, β-catenin 
mRNA was significantly upregulated exclusively in the heart compared to skeletal 
muscle, brain, spleen, liver, kidney and lung. One allele expression of BZW2 in 
heterozygous mice was sufficient to keep normal levels of β-catenin. These data 
indicate that BZW2 is necessary for the maintaining normal levels of β-catenin 
specifically in cardiac cells in line with the initial hypothesis that BZW2 may be a 




Staining analysis demonstrated apparently prominent β-catenin expression visualized 
at cell membrane in heart tissue. Hendriksen J et al., 2008 demonstrated that β-
catenin activation and recruitment at the plasma membrane generated a signaling-
competent form and is a transition effect upon Wnt stimulation, which is a more 
powerful activator of the cascade than overexpression of β-catenin.109 Moreover it is 
not yet identified, if the remaining N-terminal fragment of BZW2 is able to stabilize the 
nuclear inhibitory complex with β-catenin and KLF15. New questions have to be 
addressed, whether the remaining BZW2 peptide including the putative ZIP domain 
possess a regulatory function intervening with the Wnt cascade or whether BZW2 
exert primarily a membrane associated regulation of the β-catenin or has further 
effect downstream the cascade together with other specific factors. 
 
Bzw2 mRNA expression was found to be significantly upregulated exclusively in the 
heart tissue in the absence of KLF15, which resulted in Wnt transcriptional activation. 
In line with the data, β-catenin stabilized mice exhibited BZW2 protein upregulation in 
the heart, while no difference was observed in β-catenin downregulated mice. These 
data indicate a compensatory upregulation of BZW2 under β-catenin-dependent 
transcriptional activation. Several studies demonstrated negative regulatory effects 
by target Wnt genes like Axin2115, TCF1116 and DKK1117. Moreover, a putative 
promoter of Bzw2 showed three consensus sequences of TCF/LEF binding sites. 
Testing this fragment in luciferase assay in HEK293 showed that the overexpression 
of the target gene TCF7L2 resulted in significant increase of luciferase activity 
indirect indicating that the Wnt/β-catenin signaling positively regulates Bzw2 
transcription. These capabilities could lead to tissue- and cell-specific BZW2 
regulation. 
 
All these data together suggest that BZW2 is involved in cardiac specific inhibition of 
the Wnt/β-catenin signaling by KLF15 in adulthood. Deletion of BZW2 leads to an 
increased de novo synthesis of β-catenin exclusively in the heart. Moreover BZW2 is 




5.5. BZW2 is essential for cardiogenesis. 
Due to the pivotal role of the Wnt cascade in cardiogenesis, the role of BZW2 was 
investigated during this process in an in vitro model. Transgenic embryonic stem cell 
(ESC) lines with stable BZW2 upregulation were generated. 
Undifferentiated cells of the BZW2 overexpression lines at the differentiation day 0 
did not differ morphologically from wild type lines. Although BZW2 overexpression did 
not indicate decreased pluripotency, during the differentiation process the BZW2 
overexpression led to smaller embryoid bodies (EBs) formation compared to the wild 
type cells at days 3 and 5. According to their BZW2 upregulation levels, ESC 
transgenic lines with higher BZW2 level showed stronger impairment of EBs 
formation. To underline the molecular mechanisms of cardiomyocytes impairment 
formation, cause for EB size reduction was analyzed by expression analyses. No 
Wnt/β-catenin signaling changes were observed under BZW2 upregulation in 
undifferentiated cells, indicating initially a Wnt/β-catenin signaling independent 
differentiation impairment. Furthermore, germ layers markers were differently 
expressed at the beginning of the differentiation protocol. While the ectodermal Bmp4 
was significantly increased, the mesodermal Bry and endodermal Sox17 were 
significantly decreased, indicating that BZW2 inhibits mesoderm formation and leads 
ESCs into a more ectodermal fate. Moreover, at later differentiation day four (d4) in 
which cardiac specification occurs the cardiac mesoderm marker Mesp1 was 
significantly decreased in transgenic cells. Apart from this, at the same time point 
during cardiac specification, the Wnt/β-catenin signaling was significantly upregulated 
in transgenic cells. Since downregulation of the Wnt/β-catenin signaling is necessary 
for late cardiac specification112 these data indicate an interruption of cardiac 
specification of formed mesodermal cells under initial BZW2 upregulation. In line with 
this, at the end of the differentiation, no beating cardiomyocytes were detected 
around day 16 for BZW2 overexpressing cell lines, as normally expected. Similar to 
our data it was shown that inhibition of the Wnt/β-catenin signaling by DKK1 
treatment between d0 and d4 leads to significantly decreased expression of meso- 
and endodermal genes at d0-d4 and cardio-specific genes at d6-8 as well as 
significantly increased expression of neuroectoderm-associated genes at d6-8.54 If 
upregulation of the Wnt/β-catenin signaling activity at d4 is based on a compensatory 
response to BZW2 upregulation is unclear.  
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These data suggest that BZW2 upregulation disrupt mesoderm formation, and leads 
further to abrogation of spontaneous cardiac differentiation. Since mesoderm 
formation, an evolutionary conserved process, is the first step before cardiogenesis, 
tight regulation of BZW2 is essential for correct heart development. 
5.6. BZW2 is important for normal homeostasis and stress-induced response 
in adult heart. 
The BZW2 role in normal heart homeostasis was investigated using Bzw2 KI mice, 
described above. Echocardiography analyses revealed that mice of both genotypes 
(HE and HO) developed cardiac hypertrophy with consequent functional reduction in 
the aged mice (only aged HE investigated). This data are in line with a study 
demonstrating cardiac hypertrophy development following by dilated cardiomyopathy 
in inducible β-catenin stabilized mice under cardiac Mlc2v promoter. Those mice 
exhibited a similar but dramatically stronger phenotype.81 Moreover, β-catenin 
membrane-associated accumulation, similar to Bzw2 KI mice, was demonstrated in 
mammalian hypertrophic cardiomyopatic hearts118 indicating the important role of β-
catenin levels for maintaining normal heart structure and function. Moreover, our 
study introduces another level of regulation in which BZW2 is placed upstream of β-
catenin to control this process. 
 
BZW2 expression was found regulated upon cardiac remodeling. Angiotensin II 
induced cardiac hypertrophy in mice led to upregulated BZW2 protein expression in 
heart tissue as well as dilated (DCM) and ischemic (ICM) cardiomyopathy in human 
patients. This suggest that upon diseases condition, BZW2 is deregulated as part of 
a disease response, however the time specific regulation of BZW2 was not achieved 
in this study and is of relevance for concluding its role in the course of heart 
remodeling. 
To investigate the effect of BZW2 variation in cardiac remodeling HE Bzw2 KI mice 
exhibiting BZW2 downregulation underwent TAC, a pressure overload induced 
hypertrophy model in the heart. Cardiac morphology and function were analyzed by 
echocardiography before, 2 week and 4 weeks after operation. Anterior wall 
thickness (AWTh), heart weight relative to body weight (HW/BW) and cardiac 
function demonstrated by fraction area shortening (FAS) and ejection fraction (EF) 
were used as parameters to compare cardiac geometry and functional performance 
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after TAC. Two weeks after TAC all mice developed cardiac hypertrophy (controls 
and HE), demonstrating by significantly increased AWTh and heart mass as well as 
showed decreased cardiac function (FAS, EF). Four weeks after TAC Bzw2 KI mice 
showed reduced AWTh in systole and remained stable in diastole compared to the 
wild type mice, where AWTh slightly increased. This suggests that reduced BZW2 
leads to an earlier transition from cardiac hypertrophy to dilated myocardium under 
pressure overload-induced cardiac stress. 
 
Altogether these data suggest that long term reduction of BZW2 results in 
hypertrophy development in aged mice and leads to an earlier development of 
cardiomyopathy in the stressed heart in young mice, indicating that tight doses of 
BZW2 are important to maintain normal cardiac homeostasis under stress conditions 
such an injury or the aged heart. 
 
 
In conclusion, this study showed for the first time a comprehensive expression 
analysis of Bzw2 in embryonic development with a special focus on developing and 
mature heart tissue. These data suggest its relevance for processes of cardiogenesis 
and adult heart homeostasis. Indeed, it was shown that low levels of BZW2 are 
necessary for mesodermal formation and posterior cardiomyocytes development, 
which was impaired upon BZW2 overexpression. Concerning its role in the adult 
heart, the expression of BZW2 was shown to be necessary to maintain normal 
cardiac function and stress induced response, however its expression is apparently 
dispensable for embryonic development, may be due to compensatory genes. 
Moreover, BZW2 was shown to regulate the main component of the Wnt canonical 
cascade, β-catenin, in the adult heart. 
It was demonstrated that BZW2 is a target of the activated Wnt pathway, which may 
function as a feedback regulator in vivo. Finally, this study also provides evidences 
for the role of different protein domains, BZW2 C-terminus including W2 domain is 
important for cytosolic localization, while N-terminus including putative ZIP and bZIP 
domains is important for nuclear localization. 
Altogether, this thesis defines a novel component and a new level of regulation of the 
Wnt/β-catenin pathways specifically in heart tissue. Given the ubiquitous expression 
and multiple functions of β-catenin, tissue specific modulation under pathological 
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BZW2 expressing plasmid pcDNA3.1+-Flag-Bzw2-Neo includes Flag tagged murine 
Bzw2 transcript (mBzw2) under CMV promoter as well as ampicillin (AmpR) and 
neomycin resistance (NeoR) genes. pUC ori: origin of replication. pcDNA3.1+-Flag-









Both following modified BZW2 expressing plasmids includes puromycin resistance 
gene (PuroR). Furthermore, pcDNA3.1+-Flag-Bzw2-Puro-Orange includes an orange 













Two following plasmids are modified from pcDNA3.1+-Flag-Bzw2-Neo (pcDNA3.1+-
Flag-Bzw2-FL) and include Flag tagged truncated murine Bzw2 transcript forms. In 









Schematic view of the Bzw2 construct. ∆C and ∆N: truncated forms; ZIP, bZIP & W2: 
protein domains; AB1: antibody (Q91VK1) for staining; AB2: antibody (HPA022813) 


















The putative Bzw2 promoter sequence (1745 bp upstream the Bzw2 start codon) 
which was cloned into pGL4.10 vector. Color code: three TCF/LEF putative 
consensus sequences (blue), KpnI recognition site (light blue), NheI recognition site 
(green). 
 
